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Abstract of the Dissertation
Viral MHC Class I Evasion Affects Anti-viral T Cell Development and Responses
Elvin J. Lauron
Doctor of Philosophy in Biology and Biomedical Sciences
Molecular Microbiology and Microbial Pathogenesis
Washington University in St. Louis, 2018
Professor Wayne M. Yokoyama, Chair

Cytotoxic CD8+ T cells (CTLs) play a critical role in protective immunity against viruses,
which is underscored by the evolution of viral CTL evasion mechanisms. For instance, many
viruses commonly target the major histocompatibility complex class I (MHCI) antigen
presentation pathway to prevent CTLs from recognizing infected cells. A striking example of this
is cowpox virus (CPXV), which interferes with MHCI antigen presentation through two distinct
mechanisms. One mechanism of CPXV-mediated MHCI inhibition is to retain MHCI molecules
in the endoplasmic reticulum (ER). The second mechanism is to prevent antigen peptide loading
onto MHCI molecules. These mechanisms when combined result in potent inhibition of MHCI
antigen presentation and effective evasion of CPXV-specific CTL responses in vivo. However, it
is unclear how viral MHCI inhibition affects the CTL repertoire and the subsequent development
of memory CD8+ T cells. Furthermore, the effects of viral MHCI inhibition on local memory
CD8+ T cell responses during peripheral CPXV infection has not been examined.
To explore these issues, I used the CPXV murine infection model to compare CD8+ T
cell responses against CPXV and a recombinant CPXV mutant that is incapable of inhibiting
vii

MHCI antigen presentation. Here, I demonstrate that viral MHCI inhibition affects the local CTL
and memory CD8+ T cell repertoire in specific niches. Primary anti-CPXV responses and
memory responses were shaped by antigen abundance and CD8+ T cell cross-competition for
viral peptide-MHCI complexes on the cell surface of antigen presenting cells (APCs),
respectively. Additionally, I show that the overall quality and quantity of CTL and memory
CD8+ T cells is unaffected by viral MHCI inhibition following CPXV infection. Finally, I
determined that viral MHCI inhibition contributes to evasion of local memory CD8+ T cell
responses. Collectively, the results of these studies provide insight on determinants that influence
the anti-viral CD8+ T cell repertoire, local memory formation, and local memory responses.
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Chapter 1:
Introduction

1

Introduction to orthopoxviruses
Orthopoxviruses are large DNA viruses capable of causing devastating disease in humans
and a wide range of animal hosts. This broad host range is a feature of zoonotic orthopoxviruses,
such as cowpox virus (CPXV) and monkeypox virus (MPXV). Moreover, human MPXV
incidence has increased over 20-fold since cessation of vaccinia virus (VACV) smallpox
vaccination1, which previously provided cross-protection against MPXV, CPXV, and related
orthopoxviruses. The capacity of orthopoxviruses to infect a wide range of hosts is attributed to
their large genomes that encode a plethora of immunomodulatory proteins. Accordingly, some of
these immunoevasin proteins exhibit broad host-specificity. Here I highlight the interplay
between orthopoxvirus immunoevasins and the host immune response and discuss open
questions in regards to the effects of viral immune evasion.
Innate immunity against orthopoxvirus infection
The innate immune response can be triggered when conserved structures on pathogens,
known as pathogen associated molecular patterns (PAMPs), are detected. PAMPs are detected by
pattern recognition receptors (PRRs), which can induce signaling cascades that ultimately
converge to activate the interferon regulatory factor 3 (IRF3) and nuclear factor kappa-lightchain enhancer of activated B cells (Nf-κB)2. These transcription factors promote the expression
of proinflammatory cytokines and type I interferons (IFNs), resulting in a potent antiviral state.
This antiviral state can be initiated at several early points during orthopoxvirus infection. At the
earliest stage of infection, orthopoxviruses can be sensed when extracellular virions come in
contact with cells via toll-like receptor (TLR) 4, a cell surface PRR. TLR4 signaling restricts
viral replication and protects mice against VACV infection, as mice that are TLR4-deficient are
more susceptible to infection with VACV3.
2

VACV is also recognized at the stage of viral entry by several endosomal PRRs that
recognize pathogen-derived nucleic acids, including TLR3, 7, 8, and 94–7. Mice that are deficient
in TLR9 are also highly susceptible to orthopoxvirus infection7, while mice infected with lethal
orthopoxvirus survive when TLR9 is activated. Conversely, TLR3 signaling plays a negative role
during orthopoxvirus infection, as mice lacking TLR3 are less susceptible to VACV infection,
presumably due to excessive inflammation caused by TLR3 signaling. VACV DNA can also
activate TLR75, yet VACV infected cells do not produce IFN-α or the proinflammatory cytokine
tumor necrosis factor (TNF) through TLR7 signaling. The antiviral defense mechanisms remain
unclear for TLR7 signaling, whereas TLR4, 8, and 9-mediated innate immunity is known to
activate Nf-κB and IRF3 to induce proinflammatory cytokine and type I IFN production.
However, the production of IFN and proinflamatory cytokines is not completely dependent on
TLRs during orthopoxvirus infection3,7,8.
Orthopoxviruses can induce expression of antiviral cytokines through retinoic acidinducible gene 1 (RIG-I)-like receptors (RLRs) and cytosolic double- stranded DNA (dsDNA)
sensors (CDSs), which are cytosolic PRRs of RNA and DNA respectively. More recently, the
cytosolic sensors activating cyclic guanosine monophosphate-adenosine monophosphate
synthase (cGAS) was identified as a cytosolic DNA sensor with strong antiviral effects against
orthopoxviruses9,10. The importance of cGAS in antiviral innate immunity against
orthopoxviruses was similarly demonstrated with infections in mice that lack cGAS10. The
protective effects of cGAS are likewise mediated by Nf-κB, IRF3, and type I IFN. These
important factors are linked to RLR-mediated innate immunity against orthopoxviruses as well.
Important RLRs involved in controlling orthopoxvirus infections include RIG-I, melanoma
differentiation-associated protein 5 (MDA5), and laboratory of genetics and physiology 2
3

(LGp2)11–13. Protein kinase RNA-activated (PKR), although not an RLR, also plays an important
role in inducing type I IFN production upon sensing orthopoxvirus-derived RNA. PKR is
particularly important since activated PKR can elicit additional antiviral defense mechanisms,
such as apoptosis12.
Nonetheless, orthopoxviruses have evolved mechanisms to efficiently target the signaling
pathways of these PRRs and the activation of Nf-κB and IRF3, highlighting the importance of
these factors in the orthopoxvirus-induced innate immune response.
Orthopoxvirus evasion of innate immune responses
The central role for IRF3 and Nf-κB in innate immunity applies strong evolutionary
pressure for orthopoxviruses to evolve mechanisms of IRF3 and Nf-κB antagonism. Indeed,
orthopoxvirus immunoevasins can target the activation of IRF3 and Nf-κB directly or target
activating signaling pathways proximally. For example, the VACV proteins A46 and A52 can
disrupt TLR-mediated activation of Nf-κB by inhibiting the proximal signal transducers TNF
receptor-associated factor 6 (TRAF6) and Myd88 adapter-like (Mal) respectively. The receptorproximal adaptor proteins MyD88 and Mal initiate signal cascades when TLRs are stimulated.
MyD88 and Mal activate the IL-1 receptor-associated kinase (IRAK) or IRAK2, which in turn
recruits TRAF614. TRAF6 is essential to activate TGF-β-activated kinase 1 (TAK1) and TAK1
binding protein 1 (TAB1) dependent phosphorylation of IκB kinase (IKK)15, which is normally
in complex with Nf-κB. Phosphorylated IKK results in activated Nf-κB. The VACV protein N1
inhibits Nf-κB from being activated by associating with IKK16. The VACV protein B14 and C4
also inhibits activated IKK16,17. Importantly, C4, B14, A46, and A52 are virulence factors as
VACV mutants that lack these factors are attenuated in vivo17–20. The VACV mutant VV811
lacks 55 open reading frames (ORFs) and is missing all the known Nf-κB inhibitors.
4

Intriguingly, VV811 can still inhibit Nf-κB21, suggesting that other Nf-κB inhibitors likely
remain to be identified.
Additional poxvirus-encoded inhibitors include secreted soluble proteins that bind to
cytokines capable of inducing Nf-κB activity, thereby blocking cytokine-receptor interactions
and Nf-κB signaling. One commonly targeted cytokine is TNF, which can be intercepted by the
T2 protein from shope fibroma virus (SFV) and myxoma virus (MYXV) 22,23. T2 plays a critical
role in MYXV pathogenesis since the absence of T2 attenuates MYXV in vivo23. Similarly, TNF
binding proteins encoded by CPXV, known as cytokine response modifier (Crm) B, C, D and E,
have been shown to neutralize TNF23–25 and contribute to CPXV pathogenesis27. Crm B
orthologues are present in the genomes of multiple orthopoxviruses, including MPXV,
ectromelia virus (ECTV), and VARV28; as emphasized by the conservation of these
orthopoxvirus TNF inhibitors, orthopoxvirus fitness largely impinges on inhibiting the function
of TNF. TNF can also synergistically induce Nf-κB activity in combination with other cytokines
such as IFN-γ29. CONCLUSION?
IFN-γ is a proinflammatory cytokine that is critical in mediating anti-orthopoxvirus
immunity30–32 and is also a target of orthopoxvirus-encoded cytokine inhibitors. The secreted
IFN-γ binding protein B8 can neutralize rat, rabbit, bovine, human, equine and mouse IFN-γ and
is conserved among orthopoxviruses33,34. Deletion of B8R from the genome of ECTV
significantly attenuates ECTV pathogenesis in an IFN-γ dependent manner35. In contrast,
deletion of B8R does not have any effects on VACV and CPXV pathogenesis in mice33,36. This
may be explained by the fact that B8 from VACV and CPXV does not bind to mouse IFN-γ, yet
it is possible that VACV/CPXV B8 has alternative cytokine targets or redundant
immunomodulatory functions in mice. Interestingly, B8 also contains a conserved epitope that
5

elicits a strong immunodominant CD8+ T cell response in orthopoxvirus-infected mice bearing
the major histocompatibility complex class I (MHCI) haplotype H2b31,35–37. ßMAYBE BETTER
TO BRING UP LATER?
CONCLUSION?
OVERALL CONCLUSION FOR SECTION?
Adaptive immunity against orthopoxvirus infection
CD8+ T cells are an important arm of the adaptive immune response and play a critical
role in controlling orthopoxvirus infections. Before gaining anti-viral effector functions, CD8+ T
cells must be primed by antigen presenting cells (APCs) that present endogenous pathogenderived epitopes via MHCI molecules, a process known as direct presentation. Exogenous
antigens can also be processed through the MHCI antigen presentation pathway and presented by
APCs through a process known as cross-presentation. Upon encountering cognate antigen
epitopes presented by APCs, CD8+ T cells differentiate into cytotoxic CD8+ T cells (CTLs) and
mediate viral resistance directly by killing infected cells through secretion of the effector
molecules perforin and granzyme B or indirectly by producing IFN-γ38. In the later stages of
infection, the majority of CTLs die and a small proportion become long-lived memory CD8+ T
cells. SAY SOMETHING ABOUT NEEDING TO EXPAND A SMALL NUMBER OF VIRUSSPECIFIC CTLS DURING PRIMING. DO YOU WANT TO INTRODUCE THE
IMMUNODOMINANT ANTIGEN IDEAS HERE?
Intriguingly, CD8+ T cells alone appear to provide incomplete protection against some
orthopoxviruses and the role of CD8+ T cells in orthopoxvirus immunity was somewhat
controversial. For instance, survival following ECTV challenge was demonstrated to be
completely dependent on CD8+ T cells as CD8+ T cell depletion resulted in 100% mortality in
6

comparison to CD8+ T cell non-depleted controls39. Conversely, depletion of CD8+ T cells
during lethal CPXV infection had no effects on mortality31,36. Similarly, depletion of CD8+ T
cells during VACV infection had modest effects on viral clearance40,41, and instead CD4+ T cells
and B cells largely mediated protection40. Nevertheless, CD8+ T cells were important for
controlling VACV infection in the absence of CD4+ T cells and B cells40.
B cells contribute to viral immunity through the production of protective antibodies. The
surface antibodies on B cells serve as the B cell antigen receptor (BCR). Upon encountering
antigen, the BCR delivers the antigen for processing through the MHCII pathway. The antigen
peptide-MHC class II (pMHCII) complexes can then be presented to and recognized by CD4+ T
cells sharing the same antigen specificity42. CD4+ T cell-B cell interactions stimulates the
production of molecules that differentiate B cells into antibody-secreting plasma cells43. The
elicited antibodies can then limit the spread of virus by blocking virion attachment to cells.
Virions or infected cells bound by antibodies can also be opsonized by the complement system,
resulting in phagocytosis or killing of infected cells and virions44. Studies using ECTV and
VACV demonstrate a critical role for B cells and CD4+ T cells, where deficiencies in either cell
types results in death following viral challenge40,45,46, despite the mounting of a normal CD8+ T
cell response. CD8+ T cell responses can however complement CD4+ T cell and B cell responses
during orthopoxvirus infection40,45.
Orthopoxvirus evasion of adaptive immunity
Given the importance of T and B cells in immunity against orthopoxviruses, it is no
surprise that orthopoxviruses have evolved mechanisms to thwart the function of these adaptive
immune cells. One such mechanism is to prevent the complement system from activating.
VACV encodes a complement binding protein called vaccinia complement-control protein
7

(VCP). VCP prevents complement proteins from acting on antigen-bound antibodies47. Skin
infection with VCP deficient VACV results in reduced lesion size in comparison to infection
with VCP sufficient VACV48. Therefore, VCP is a virulence factor that indirectly inhibits
antiviral antibodies produced by B cells.
Other mechanisms to evade B cell and CD4+ T cell functions have been reported, yet the
in vivo relevance remains to be determined. For instance, MPXV and CPXV encode an
orthopoxvirus MHC class I-like protein (OMCP) that binds to an immunoregulatory receptor
expressed on B cells. These findings strongly suggest a role for OMCP in evading B cell
responses49. Additionally, B cell MHCII antigen presentation to CD4+ T cells can be inhibited
when B cells are infected with VACV50, implying that VACV may also prevent CD4+ T cell-B
cell interactions in vivo. MPXV also encodes an immunoevasin that effectively suppresses both
CD4+ T cell and CD8+ T cell stimulation, although MPXV does not inhibit MHCII and MHCI
antigen presentation51.
While many viruses target antigen processing and presentation through the MHCI
pathway in order to evade anti-viral CTLs, CPXV is the only orthopoxvirus capable of doing
so31,36,52,53. There are two CPXV encoded proteins that inhibit MHCI antigen presentation,
CPXV203 and CPXV012. CPXV012 prevents MHCI molecules from being loaded with antigen
by binding to transporter associated with antigen processing (TAP) molecules, whereas
CPXV203 binds to and retains MHCI in the ER of infected cells52,53. The combined functions of
CPXV203 and CPXV012 effectively prevent CPXV-specific CTLs from recognizing infected
target cells, resulting in significant consequences in vivo.
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Investigating the effects of viral MHCI evasion on CD8+ T cell effector function and
development.
CPXV-mediated MHCI inhibition effectively evades CPXV-specific CTL effector
functions, but does not affect priming of naïve CPXV-specific CTL precursors. Direct priming is
likely abrogated since CPXV-infected APCs are also subjected to CPXV-mediated MHCI
inhibition53. However, following CPXV infection, CD8α+/CD103+ dendritic cells (BATF3+ DCs)
prime naïve CTL precursors, suggesting that the induction of anti-CPXV CTL responses is
dependent on cross-presenting BATF3+ DCs subsets31,36. Although BATF3+ DCs induce a strong
anti-CPXV CTL response, CPXV-specific CTLs alone are ineffective at controlling CPXV
infection and depletion of CD8+ T cells has no effects on mortality or survival during lethal
CPXV infection31,36,52. Strikingly, infection with a CPXV mutant lacking the endogenous viral
MHCI inhibitors (Δ12Δ203) induces a CTL response that is also dependent on BATF3+ DCs, but
Δ12Δ203 is significantly attenuated in vivo in comparison to WT CPXV. In the absence of
CPXV012 and CPXV203, CTLs are critical in viral clearance since mice depleted of CD8+ T
cells succumb to infection with Δ12Δ203. Furthermore, in the absence of CD4+ T cells and B
cells, CPXV-specific CTLs are sufficient in providing protection against Δ12Δ203, but not WT
CPXV31.
Interestingly, infection with both WT CPXV and Δ12Δ203 results in local CTL response
dominated by the viral epitope B819-26, which is restricted to the H-2Kb MHCI allomorph31. This
phenomenon, known as immunodominance, has been investigated using VACV54–57. However,
VACV does not inhibit MHCI antigen presentation58. Therefore, the determinants of
immunodominance have not been thoroughly interrogated in a context where viral MHCI
inhibition has significant consequences in vivo. Likewise, the effects of viral MHCI inhibition on
9

immunodominance within the memory CD8+ T cell pool, memory CD8+ T cell development in
general, and memory CD8+ T cell effector functions remain unclear.
To address these issues, I compared primary CD8+ T cell and memory CD8+ T cell
responses against WT CPXV infection to the respective responses against Δ12Δ203 infection. In
chapter 2, I present my study on CD8+ T cell immunodominance during CPXV infection and
discuss the factors that influence immunodominance in the presence of viral MHCI inhibition. I
then present my study on memory CD8+ T cell formation/responses following CPXV infection
and discuss the effects of viral MHCI inhibition on these processes in chapter 3. Finally, in
chapter 4, I discuss the implications of these findings and additional questions that stem from my
studies.
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Chapter 2:
Cross-priming induces immunodomination in
the presence of viral MHC class I inhibition
This chapter was published as a research article in PLOS Pathogens (2018).

Authors: Elvin J. Lauron1, Liping Yang1, Jabari I. Elliott2, Maria D. Gainey3, Daved H.
Fremont2,4,5, Wayne M. Yokoyama6,*
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Department of Medicine, Washington University School of Medicine, St. Louis, Missouri,

United States of America, 2Department of Pathology and Immunology, Washington University
School of Medicine, St. Louis, Missouri, United States of America, 3Department of Biology,
Western Carolina University, Cullowhee, North Carolina, United States of America,
4

Department of Biochemistry and Molecular Biophysics, Washington University School of

Medicine, St. Louis, Missouri, United States of America, 5Department of Molecular
Microbiology, Washington University School of Medicine, St. Louis, Missouri, United States of
America, 6Division of Rheumatology, Washington University School of Medicine, St. Louis,
Missouri, United States of America
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Abstract
Viruses have evolved mechanisms of MHCI inhibition in order to evade recognition by cytotoxic
CD8+ T cells (CTLs), which is well-illustrated by our prior studies on cowpox virus (CPXV) that
encodes potent MHCI inhibitors. Deletion of CPXV viral MHCI inhibitors markedly attenuated
in vivo infection due to effects on CTL effector function, not priming. However, the CTL
response to CPXV in C57BL/6 mice is dominated by a single peptide antigen presented by H2Kb. Here we evaluated the effect of viral MHCI inhibition on immunodominant (IDE) and
subdominant epitopes (SDE) as this has not been thoroughly examined. We found that crosspriming, but not cross-dressing, is the main mechanism driving IDE and SDE CTL responses
following CPXV infection. Secretion of the immunodominant antigen was not required for
immunodominance. Instead, immunodominance was caused by CTL interference, known as
immunodomination. Both immunodomination and cross-priming of SDEs were not affected by
MHCI inhibition. SDE-specific CTLs were also capable of exerting immunodomination during
primary and secondary responses, which was in part dependent on antigen abundance.
Furthermore, CTL responses directed solely against SDEs protected against lethal CPXV
infection, but only in the absence of the CPXV MHCI inhibitors. Thus, both SDE and IDE
responses can contribute to protective immunity against poxviruses, implying that these
principles apply to poxvirus-based vaccines.
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Introduction
Strategies to leverage strong CD8+ cytotoxic T lymphocyte (CTL) responses to viral
infections are of particular interest as CTLs play essential roles in controlling viral infections
31,52,59–61

. Before gaining effector functions, virus-specific CTL precursors must be primed by

antigen presenting cells (APCs) that present pathogen-derived epitopes via major
histocompatibility complex class I (MHCI) molecules on the cell surface. If the APC is infected
and directly presents endogenously produced antigens, this is known as direct presentation.
Alternatively, uninfected APCs may process and cross-present exogenous antigens from infected
cells. Cross-presentation is mediated primarily by Batf3-dependent CD103+/CD8α+ dendritic
cells (DCs) 62–64, which we refer to as BATF3+ DCs. Peptide-loaded MHCI molecules from
infected cells may also be liberated by cell lysis or secreted in exosomes and then transferred
onto cross-presenting APCs. When uninfected APCs acquire preformed peptide-MHCI
complexes in this manner, they are termed cross-dressed and can drive expansion of CD8+ T
cells 65–67. Induction of CD8+ T cell responses by cross-dressing was previously demonstrated in
studies using adoptive transfer of T cell receptor (TCR) transgenic (Tg) T cells 65–67 and also
requires BATF3+ DCs 67. However, the relative contribution of these processes to non-TCR Tg
CTL responses against viral antigens is largely unknown.
Upon recognizing cognate antigen on APCs, naïve CTLs are activated to undergo clonal
expansion and traffic to the site of ongoing viral infection. There, virus-specific CTLs mediate
host resistance by recognizing infected cells via surface MHCI molecules displaying processed
viral antigens. Specific T cell recognition activates direct killing of infected cells and production
of interferon-gamma (IFN-γ) and other cytokines that may have indirect effects. In the later
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stages of the response, a proportion of CTLs become long-lived memory CD8+ T cells that can
provide rapid protection during secondary responses to the viral pathogens.
Many viruses display mechanisms that may contribute to evading CTL responses, such as
inhibiting MHCI antigen presentation. The effects and mechanisms of MHCI inhibition on CTL
responses have been well demonstrated in vitro with herpesviruses 68. For instance,
downregulation of MHCI by murine cytomegalovirus (MCMV) prevented MCMV-specific
CTLs from killing infected cells, whereas cells infected with an MCMV mutant lacking the viral
MHCI inhibitors were lysed by CTLs 69. However, the in vivo relevance of viral MHCI
inhibition in general was previously unclear since herpesvirus-mediated MHCI inhibition had
few effects on in vivo CTL responses in murine and nonhuman primate infection models 70–72.
On the other hand, studies of cowpox virus (CPXV) by our lab and others indicated that
CPXV, uniquely among the orthopoxviruses, mediated mouse and human MHCI inhibition by
two open reading frames (ORFs), CPXV012 and CPXV203 52,53,73. CPXV203 retains MHCI
molecules in the ER and CPXV012 inhibits peptide loading on MHCI molecules; when
combined, these two evasion mechanisms allows CPXV to evade CTL responses. The deletion
of intact CPXV012 and CPXV203 from the CPXV genome attenuated viral pathogenesis in vivo
31,52

. Furthermore, this attenuation was dependent on the anti-CPXV CTL response since

depleting CD8+ T cells restored the virulence of the Δ12Δ203 CPXV mutant, similar to wild type
(WT) CPXV. Thus, these studies of CPXV established the in vivo importance of viral MHCI
inhibition and its effects on antiviral CTL responses.
Interestingly, the virus-specific CTL response to CPXV in C57BL/6 mice is dominated
by a single antigen (B8), displaying the immunological phenomenon known as
immunodominance, that can impede the development of efficacious vaccines 74. In theory,
14

removing the IDE(s) may circumvent immunity. However, for some viruses, subdominant
epitopes (SDEs) may compensate and then dominate the immune response 35,75. Such findings
revealed that responses against an IDE(s) suppress immune responses to SDEs, which is a related
yet distinct phenomenon coined immunodomination. CD8+ T cell immunodomination also
occurs during secondary responses whereby memory CD8+ T cells can suppress naïve CD8+ T
cell responses 54. CD8+ T cell immunodomination is likely a mechanism that contributes to the
immunodominance of the B8 antigen in CPXV infections 55, but has not been studied in the
context of MHCI inhibition.
B8R is a highly conserved gene among orthopoxviruses and encodes the secreted soluble
B8 protein that binds IFN-γ with broad species-specificity. B8 from ectromelia virus (ECTV) is a
strong inhibitor of human, bovine, rat, and murine IFN-γ 34, but VACV and CPXV B8 does not
neutralize murine IFN-γ 76. These differences have been attributed to host-specificity. While the
natural host of ECTV is not known, experimentally it is restricted to murine hosts, whereas
VACV has a broad host-tropism with an unknown natural reservoir 77. The natural reservoirs of
CPXV are wild-rodent species, but CPXV also has broad host-tropism 78,79. Despite these
differences, B8 is the most dominant antigen identified in mice with the H-2Kb MHCI allele, and
the B8 CD8+ T cell epitope sequence (TSYKFESV) is 100% conserved between ECTV, VACV,
CPXV, and other orthopoxviruses 37. However, it is not clear if B8 is an immunodominant
antigen because it is a secreted soluble protein that may be efficiently cross-presented.
Previously, we showed that CPXV infection of Batf3-/- mice that selectively lack the main
cross-presenting DC subsets (CD103+/CD8α+ DCs) 80 display reduced priming of B819-26-specific
CD8+ T cells during CPXV infection 31, suggesting that cross-presentation is a major pathway
used to induce CTLs. However, since Batf3–/– mice also lack the capability of cross-dressing, it is
15

also possible that cross-dressing is the main pathway to induce CPXV-specific CTLs. Moreover,
it remained unclear whether other CPXV antigens (i.e., SDEs) are efficiently presented by
BATF3+ DCs because CPXV B819-26 immunodominates the primary CTL response 31. Finally,
due to the above limitations, it is not known if these processes could be affected by viral MHCI
inhibition.
Here we studied if transmembrane anchoring of B8 affects its immunodominance, the
role of MHCI inhibition in the generation of virus-specific CTLs to SDEs and for the first time,
the relevance of cross-dressing in the induction of endogenous antiviral CTL responses.

Results
Secretion of the immunodominant antigen is not a determinant for immunodominance
The immunodominant CPXV B8 antigen is a secreted soluble protein 34, suggesting that
its immunodominance may be due to its property as a secreted molecule, as shown for other
antigens 81,82. If this were true, we expect that altering the protein targeting of B8 so that it is no
longer secreted from infected cells will affect the acquisition and availability of B8 for APCs,
which in turn would affect priming of B819-26-specific CD8+ T cells and its immunodominance.
To test these hypotheses and detect subcellular location of B8, we produced a CPXV mutant
expressing B8 fused to mCherry (B8mC) and another mutant (B8TMmC) expressing B8mCherry fusion protein with a transmembrane domain (TMD) (Fig 2.1A).
We performed subcellular fractionation of infected HeLa cells and analyzed the
cytoplasmic extract, membrane extract, and supernatant by Western blot to determine the
subcellular location of the B8 variants and if they were secreted. The B8 variants were mainly
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detected in the membrane extract of both B8TMmC- and B8mC-infected cells, indicating that the
infected cells successfully expressed both B8 variants (Fig 2.1B). We note that the membrane
fraction may contain proteins found within the mitochondria and endoplasmic reticulum, but not
nuclear proteins, such that the secreted B8 variant detected in the membrane fraction is likely due
to proteins localized within the ER and in transit through the secretory pathway. We also
detected higher levels of the non-secreted B8 variant in the membrane fraction in comparison to
the secreted variant, which is likely due to an accumulation of membrane-associated B8 within
B8TMmC-infected cells. Most importantly, the B8 variant was detected in the supernatant of
cells infected with B8mC, but not in the supernatant of cells infected with B8TMmC,
demonstrating that the B8 variant remains cell-associated in cells infected with B8TMmC (Fig
2.1B). However, anchoring the B8 antigen did not negatively affect priming of B819-26-specific
CD8+ T cells and B819-26 maintained the highest position in the immunodominance hierarchy, as
shown in mice infected intranasally (i.n.) with B8TMmC or B8mC (Fig 2.1C and 2.1D). These
data show that secretion of the B8 antigen is not required for priming of B819-26-specific CD8+ T
cells or immunodominance during CPXV infection.
We also performed kinetic analyses of B819-26-specific CD8+ T cells by staining with
H2Kb tetramers loaded with B819-26 peptide and found that priming by cell-associated B8
resulted in greater expansion of B819-26-specific CD8+ T cells (Fig 2.1E). These results are
consistent with previous findings that cell-associated antigens are cross-presented better than
soluble antigens 83,84. When we infected Batf3-/- mice with B8TMmC or B8TM, we found that
priming of B819-26 -specific CD8+ T cells was significantly reduced in Batf3-/- mice in
comparison to B6 mice (Fig 2.1F), indicating that the introduced B8 mutations did not alter the
dependence on cross-presentation (or cross-dressing) in the induction of B819-26-specific CTL
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precursors. Since priming against the non-secreted B8 protein is still dependent on crosspresenting (or cross-dressed) BATF3+ DCs, it is likely that antigens used for conventional crosspresentation by BATF3+ DCs are acquired from infected apoptotic/necrotic donor cells or that
BATF3+ DCs are cross-dressed with peptide-loaded MHCI molecules.

Cross-presentation, but not cross-dressing of APCs, drives CTL responses during CPXV
infection
While we previously reported that priming of CD8+ T cell responses to CPXV is
dependent on cross-presenting BATF3+ DCs, others reported that direct priming is the main
mechanism to induce CTL responses with VACV infection 85,86. To directly compare these
findings, we assessed the CTL response after systemic infection with WT CPXV, Δ12Δ203
(from here on referred to as ΔMHCIi) CPXV, or VACV in B6 and Batf3-deficient mice. At 8
days post-infection (dpi), the frequency of splenic CD8+ T cells that produced IFN-γ in ex vivo
stimulations with ΔMHCIi-infected DC2.4 cells was significantly reduced in WT CPXV- and
ΔMHCIi-infected Batf3-/- mice (Fig 2.2A) in comparison to infected B6 mice, confirming the
importance of cross-presentation (or cross-dressing) in inducing CPXV-specific CTLs, as we
showed earlier 31. Conversely, at 6 or 8 dpi, ex vivo stimulation with a set of 5 VACV/CPXV
peptides (Fig 2.2B) or VACV-infected DC2.4 (Fig 2.2A) revealed no significant difference in the
VACV-specific response between infected B6 and Batf3-/- mice. These results are consistent with
the findings that ablation of XCR1-expressing (CD103+/CD8α+) DCs does not completely
abolish priming of CD8+ T cells during VACV infection 87. Thus, the in vivo responses to two
highly related orthopoxviruses display distinct requirements for direct presentation (VACV)
versus cross-presentation/cross-dressing (CPXV).
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Given that priming of CPXV-specific CTL precursors and cross-dressing of APCs in
other settings were both shown to require BATF3+ DCs 67, we sought to determine if crossdressing could account for the source of antigen being presented to CD8+ T cells in CPXV
infection. To do so, we transferred B6 bone marrow into lethally irradiated Batf3-/--F1 (Batf3-/-B6 x Batf3-/--BALB/c) mice (Fig 2.3A). In B6àBatf3-/--F1 chimeras, donor B6-derived (Batf3dependent) APCs only express H-2b MHCI molecules and should cross-prime CTL responses
against H2b-restricted epitopes (Fig 2.3A). However, priming by H-2d-restricted epitopes would
occur only if the H2b APCs in these chimeric mice were cross-dressed with preformed peptideloaded H-2d class I molecules from the host parenchymal cells, which express both H-2b and H2d class I molecules. We also produced BALB/càBatf3-/--F1 chimeras, to analyze the converse
situation. The reconstituted mice were infected by i.n. administration with WT CPXV and CTL
responses were determined against the immunodominant H-2Kb-restricted B819-26 and the H-2Ldrestricted F226-34 epitopes. As expected, we detected a B819-26 response in B6àBatf3-/--F1 mice
that was of similar magnitude to non-chimeric WT-F1 (B6 x BALB/c) infected mice (Fig 2.3B).
We also detected a small B819-26-specific response in BALB/càBatf3-/--F1, but the frequency of
B819-26-specific CD8+ T cells was significantly lower (~12-fold) than in B6àBatf3-/--F1 and WTF1 mice. A small, yet detectable response to F226-34 was also detected in the lungs of B6àBatf3-/-F1-infected mice, but it was ~3 fold and ~8 fold lower in comparison to WT-F1- and
BALB/càBatf3-/--F1-infected mice respectively. Thus, these data suggest cross-dressing
contributes minimally to priming against these peptide determinants.
It is possible that cross-dressing by H-2Kb- and H-2Ld-restricted epitopes other than B81926

and F226-34, respectively, occurred in infected BMC mice, so we also performed ex vivo

stimulations with ΔMHCIi-infected DC2.4 (H-2b) and P815 (H-2d) cells as these cells present a
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broad array of naturally derived CPXV peptides (Fig 2.3B). The frequency of IFN-γ+ CD8+ T
cells upon stimulation with ΔMHCIi-infected DC2.4 cells was significantly lower in
BALB/càBatf3-/--F1 mice in comparison to B6àBatf3-/--F1 and WT-F1 mice. Similarly, the
frequency of IFN-γ+ CD8+ T cells upon stimulation with ΔMHCIi-infected P815 cells was
significantly lower in B6àBatf3-/--F1 mice in comparison to BALB/càBatf3-/--F1 and ~10 fold
lower in comparison WT-F1 mice. The frequency of CD8+ T cells that responded to ΔMHCIiinfected P815 cells was also significantly lower in WT-F1 in comparison to BALB/càBatf3-/--F1.
This was also seen in F226-34 responses (Fig 2.3B). These findings may be due to the additional
epitope diversity from H-2b as well as H-2d expression in WT-F1, which may compromise
responses to H-2d-restricted epitopes during the primary response. Regardless, these results
suggest that cross-dressing from non-hematopoietic cells does not generate a vigorous response
during primary CPXV responses.
We next assessed whether cross-dressing plays a role during secondary responses to
CPXV infection since cross-dressed APCs are capable of stimulating memory CD8+ T cells 65.
However, the secondary CPXV response in the B6àBatf3-/--F1 and BALB/càBatf3-/--F1 mice
were similar to what was observed in the primary CPXV response (Fig 2.3C). Thus, crossdressing from non-hematopoietic cells also plays a minor role in activating endogenous memory
CD8+ T cells following CPXV infection.
To test if cross-dressed MHCI could be contributed by the hematopoietic compartment,
we reconstituted lethally irradiated Batf3-/--F1 mice with a 1:1 mixture of BALB/c-Thy1.1 and
Batf3-/--F1 bone marrow (S2.1A Fig). In these mice, cross-presentation should only be carried out
by the donor BALB/c-Thy1.1-derived APCs (H-2d). In contrast, cells that are of the donor Batf3/-

-F1 (H-2b x H-2d) origin will lack BATF3+ DCs and should not carry out cross-presentation, but
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may serve as a source of cross-dressing peptide-MHCI complexes. We systemically infected
BALB/c-Thy1.1 + Batf3-/--F1àBatf3-/--F1 mice with WT CPXV and found that the H-2drestricted response was successfully reconstituted, whereas the H-2b-restricted response was
significantly lower than the response in WT-F1 mice and was comparable to Batf3-/--F1àBatf3-/-F1 control mice (S2.1B Fig). These data indicate that APCs cross-dressed from other
hematopoietic cells does not efficiently prime CD8+ T cell responses in the setting of effective
viral MHCI inhibition.
Taken together, these data suggest that antigens are predominantly cross-presented by
BATF3+ DCs during CPXV infection and that cross-dressing plays a minor role, if at all.

Cross-presentation of SDEs in the absence of the IDE induces a robust CD8+ T cell
response that is not affected by viral MHCI inhibition, revealing immunodomination
Insufficient cross-presentation of SDEs may explain the subdominance of other CPXV
antigens. To test if cross-presentation of CPXV SDEs alone is capable of inducing a strong CTL
response, we mutated the B819-26 epitope anchor residues required for binding to H-2Kb peptidebinding groove, postulating that this will prevent the B819-26 epitope from being presented by H2Kb. According to the peptide-binding motif of H-2Kb, the B819-26 epitope contains a primary
anchor residue (phenylalanine at position P5) and an auxiliary anchor residue (tyrosine at
position P3) 88. To determine whether mutating the primary anchor residue is sufficient to
eliminate binding to H-2Kb or if both anchor residues should be mutated, peptide-binding assays
were performed using the transporter associated with antigen processing 2 (TAP2)-deficient
RMA-S cell line in which addition of peptides capable of binding H-2Kb stabilize its expression
on the cell surface 89. Alanine substitution of the primary anchor residue significantly reduced
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binding of the B819-26 epitope peptide to H-2Kb as compared to WT B8, but binding could be
increased with increasing concentrations of peptide (S2.2A Fig). However, alanine substitutions
of the primary and auxiliary anchor residues completely abrogated binding of the B819-26 epitope
peptide to H-2Kb, even at higher peptide concentrations. Based on these findings, we introduced
both substitutions into the WT and the ΔMHCIi CPXV genomes. The CPXV B819-26 epitope
mutants B8Y3AF5A (referred to as ΔB819-26) and a B8R deletion mutant (ΔB8R) that we
generated did not exhibit defects in viral replication in vitro (S2.2B Fig). Surprisingly, they also
did not show attenuated virulence in vivo, as measured by weight loss or lethality, as compared
to WT CPXV (S2.2C Fig).
There was no detectable B819-26 response in ΔB819-26- or ΔMHCIiΔB819-26-infected mice
(Fig 2.4A and 2.4B, S2.3A and S2.3B Fig). However, infections with ΔB819-26 or ΔMHCIiΔB819-26 generated a robust SDE response. In contrast, as we previously reported 31, a large
proportion of the CPXV-specific CTL response was directed against B819-26 in the lungs of WTand ΔMHCIi-infected mice. Additionally, there were no significant differences between the
overall CTL responses against WT, ΔB819-26, ΔMHCIi, and ΔMHCIiΔB819-26 (Figs 2.4A and
2.4B), despite the loss of the B819-26-specific response. Therefore, the CTL response was
completely compensated by SDEs in the absence of a B819-26 response.
It was possible that the B819-26 epitope mutation allows CPXV to replicate to higher titers
in the lungs of infected mice resulting in higher antigen loads, which could explain the observed
compensation. However, the B819-26 epitope mutations did not result in significantly increased
viral titers in infected mice (Fig 2.4C), suggesting that the compensation is unlikely due to
increased antigen loads.
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Immunodomination and priming by SDEs were also not affected by CPXV-mediated
MHCI inhibition since there were no significant difference in the SDE response against ΔB819-26
and ΔMHCIiΔB819-26, as measured by stimulation with ΔMHCIi- (used to estimate total
response) or ΔMHCIiΔB819-26- (used to estimate total SDE response) infected DC2.4 cells (Fig
2.4A and 2.4B). Additionally, there was no significant difference in the frequency of CD8+ T
cells that exhibited an effector T cell phenotype in infected mice (S2.3C and S2.3D Fig).
Considering that the route of infection can alter antigen levels and immunodominance 55, we
infected mice by intraperitoneal (i.p.) injections. Compensation by SDEs was also observed
during systemic infection (Figs 2.4D and 2.4E), suggesting that compensation was not dependent
on antigen levels or the route of infection. However, CTL responses against the panel of
subdominant epitopes we tested were not significantly increased in the absence of B819-26,
suggesting that other unidentified or cryptic subdominant epitopes compensated the CTL
response. Interestingly, the response against A4288-96 was significantly reduced in the absence of
the B819-26-specific response (Fig 2.4D), suggesting that SDEs were up-ranked in the dominance
hierarchy and were now themselves eliciting immunodomination. Furthermore, we found that
priming of SDE-specific CD8+ T cells was also dependent on BATF3+ DCs (S2.3E Fig). These
data suggest that the IDE-specific CTL response suppresses cross-priming of SDE-specific CD8+
T cells during primary CPXV infections, indicating immunodomination, but this process was not
affected by viral MHCI inhibition.

SDE-specific CD8+ T cell are effective at immunodomination during primary and
secondary CPXV infection
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Memory CD8+ T cells also have a capacity for immunodomination and can inhibit naïve
CD8+ T cell responses 54. However, this is not the case for VACV since prior priming with
individual SDEs does not alter the immunodominance hierarchy following VACV boost in SDEprimed mice 56. Considering that the priming mechanisms are different during VACV and CPXV
infection (Fig 2.2A), we tested whether CPXV-specific memory CD8+ T cells can exert
immunodomination. We primed mice with WT CPXV, boosted the mice with a low or high dose
of ΔB819-26 at 25 dpi, and assessed the CD8+ T cell response in the lungs and spleens 8 days after
boosting (Fig 2.5A). In this group, B819-26-specific memory CD8+ T cells should be present preand post-boost, but will not undergo expansion following boost with ΔB819-26. As expected, we
detected B819-26-specific CD8+ T cells in the lungs and spleens of WT CPXV-primed mice after
boosting with ΔB819-26 (Fig 2.5B and 2.5C) and before boosting (Fig 2.5D). Additionally, we
found that WT and ΔMHCIi infection resulted in a similar relative abundance of B819-26-specific
CD8+ T cells with a memory phenotype (CD44+CD62L+KLRG1-CD127+) at 25 dpi, suggesting
that viral MHCI inhibition does not affect memory T cell development (Fig 2.S4). In a separate
group, mice were primed with SDEs by ΔB819-26 infection and boosted with WT CPXV. In this
group, we would expect mice to mount a naïve B819-26 response after boosting with WT CPXV
only in the absence of memory CD8+ T cell immunodomination. However, the naïve B819-26
response was significantly inhibited following boost with both a low and high dose of WT
CPXV, suggesting that the SDE-specific memory CD8+ T cells immunodominate naïve CD8+ T
cells. Alternatively, neutralizing antibodies may have reduced the antigen levels and therefore
limited the naïve B819-26 response following boost with CPXV.
To assess the potential role of host-protective antibodies, we repeated the above
experiments, but this time we depleted CD8+ T cells prior to challenging mice with CPXV
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(S2.5A and S2.5B Fig) and then monitored the mice for survival. CPXV-immunized mice that
received CD8-depleting or isotype control antibodies survived, whereas naïve mice succumbed
to the challenge (S2.5C Fig). Although this was somewhat expected because CPXV evades
CTLs, these results suggest that host-protective antibodies may contribute to protection in the
absence of CD8+ T cells during secondary exposure to CPXV. We thus repeated the prime and
boost experiments and examined immunodomination in µmT mice, which lack mature B cells.
Because CPXV evades CTLs in vivo and µmT mice should not mount a protective antibody
response, it is likely that µmT mice are highly susceptible to WT CPXV infection. To avoid this
issue, we infected µmT mice with ΔMHCIi CPXV strains as CTLs can effectively control these
viruses in WT mice. We primed µmT mice by skin scarification (s.s.) infection, which resembles
human immunizations with VACV. We then boosted the mice at 25 dpi by i.n. administration,
and subsequently assessed the CD8+ T cell response 7 days after boost. Mice primed with
ΔMHCIi resulted in expansion of a B819-26-specific CD8+ T cells following i.n. boost with
ΔMHCIi (Fig 2.5E). Mice primed with ΔMHCIiΔB819-26 also mounted a detectable response
against B819-26 following i.n. boost with ΔMHCIi, yet this response was significantly reduced by
~9-fold in comparison to mice immunized with ΔMHCIi. Therefore, memory CD8+ T cell
immunodomination still occurred in the absence of neutralizing antibodies and viral MHCI
inhibition, suggesting that immunodomination may be due to T cell interference.
Because memory CD8+ T cells are present at higher frequencies than naïve antigenspecific CD8+ T cells, it is likely that memory CD8+ T cells have a competitive advantage in
accessing APC resources 90–92. For instance, downregulation of MHCI on infected cells may
limit the level of antigen presented during CPXV infection, thereby contributing to T cell crosscompetition for peptide-MHCI complexes in the secondary response. Indeed, T cell cross25

competition for peptide-MHCI complexes during secondary responses has been demonstrated
using a heterologous prime-boost strategy 93, but to our knowledge this has only been directly
tested between memory and naïve T cells specific for IDEs. To test if SDE-specific memory
CD8+ T cells can cross-compete with naïve B819-26-specific CD8+ T cells, we performed a
competition experiment in which we primed mice with ΔB819-26, adoptively transferred peptidepulsed BMDCs at 25 dpi, and then assessed the CD8+ T cells responses 6 days after transfer.
Transfer of B819-26-pulsed BMDCs into ΔB819-26 -primed mice resulted in a robust B819-26
response (Fig 2.5F). Likewise, transfer of K36-15-pulsed BMDCs resulted in moderate expansion
of K36-15-specific memory CD8+ T cells. However, when BMDCs that were pulsed with B819-26
and K36-15 at the same time were transferred the B819-26 response was inhibited, further
supporting the findings that memory CD8+ T cells immunodominate naïve CD8+ T cells.
Conversely, B819-26-specific CD8+ T cells dominated the response when BMDCs pulsed with
B819-26 and K3L6-15 at the same time were transferred into naïve mice (Fig 2.5G). If
immunodomination is an effect of cross-competition, then providing BMDCs that exclusively
present K36-15 and BMDCs that exclusively present B819-26 alone should overcome the effects of
immunodomination. When B819-26-pulsed BMDCs were mixed with K36-15-pulsed BMDCs
(pulsed separately) and transferred into ΔB819-26-primed mice, the B819-26 response was
significantly greater than in mice that received BMDCs pulsed with B819-26 and K3L6-15 at the
same time, suggesting that cross-competition plays a role in memory CD8+ T cell
immunodomination.
Interestingly, the B819-26 response in mice that received the 1:1 mixture of K3L6-15-pulsed
and B819-26-pulsed BMDCs was significantly lower than in mice that only received B819-26pulsed BMDCs. Therefore, the partial rescue of the B819-26 response when the epitopes were
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presented on different APCs suggest that additional factors contribute to immunodomination
during secondary responses. In contrast to the secondary response, separating the K36-15 and
B819-26 epitopes during primary responses had no effect on immunodomination of B819-26specific CD8+ T cells (Fig 2.5G), suggesting that cross-competition for peptide-MHCI
complexes contributes to immunodomination mainly during secondary responses.
Having demonstrated that SDE-specific memory CD8+ T cells have a capacity for
immunodomination, we asked if SDE-specific CD8+ T cells could exhibit immunodomination
during primary responses. We reasoned that modulating the immunodominant and subdominant
antigen levels may allow SDE-specific CD8+ T cells to immunodominate. To test this, we
performed co-infection experiments in which the level of WT and ΔB819-26 input were varied
while maintaining the overall viral dose. We first synchronized the infections to limit the
variation in the dose by infecting freshly harvested splenocytes with either WT or ΔB819-26
separately. We then mixed WT- and ΔB819-26-infected splenocytes at a ratio of 1:0, 10:1, 1:10, or
0:1, inoculated mice i.v. with a total of 1 x 105 infected cells, and assessed the CTL response at 7
dpi (Fig 2.6A). A graded B819-26 response was observed with the concurrent increase of ΔB819-26
input and decrease of WT input (Fig 2.6B), while the overall response as determined by
stimulation with ΔMHCIi-infected DC2.4 cells remained roughly equal (Fig 2.6C). These data
suggest that SDE-specific CTLs are capable of immunodominating the primary response when
the relative abundance of subdominant antigens is increased, even in the presence of the IDE. To
confirm that the graded response was not simply due to reduced WT input, we repeated the coinfection experiment using mixtures of WT- and mock-infected splenocytes. Injecting the
varying mixtures of WT- and mock-infected splenocytes did not result in a gradation of the B819-
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response (Fig 2.6B), suggesting that the observed graded B819-26 response was dependent on

the subdominant antigen levels.

SDE-primed CD8+ T cells control lethal CPXV infection in the absence of the CPXV MHCI
inhibitors
Thus far, our results indicate that CPXV-mediated MHCI inhibition does not affect
priming of CD8+ T cells by SDEs. However, we wondered whether SDE-specific CTL responses
could provide protection against CPXV infection in vivo. To examine the physiological
relevance of SDEs in protecting against CPXV infection, we performed adoptive transfer
experiments with CTLs primed with ΔB819-26 or MCMV as a control for antigen specificity (Fig
2.7A). Mice that received primed CTLs were then challenged by i.n. administration with a lethal
dose of ΔB819-26 or ΔMHCIiΔB819-26. The majority of mice that received MCMV-primed CTLs
died following infection with ΔB819-26 or ΔMHCIiΔB819-26 (Fig 2.7B and 2.7C). All mice that
received ΔB819-26-primed CTLs also died after challenge with ΔB819-26, whereas all mice
challenged with ΔMHCIiΔB819-26 survived. Therefore, CTLs primed by SDEs are capable of
recognizing and controlling CPXV only in the absence of CPXV-mediated MHCI inhibition,
which is consistent with our previous findings regarding WT CPXV exposure that is dominated
by the B819-26 response 31,52.

Discussion
Headings may be typed above or on the same line as the sections they label. Type the
chapter number and section number before the section title. The font size for section headings
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should be no larger than 18. Here we demonstrate that the secretion of an immunodominant
CPXV antigen does not affect immunodominance or cross-priming by the IDE. Intriguingly, we
found that the IDE and SDEs are differentially presented by APCs during infection with CPXV
and VACV, despite being closely related genetically. We also show that CD8+ T cell
immunodomination is not affected by viral MHCI inhibition and can be elicited by SDEs during
primary and secondary responses against CPXV infection. Additionally, we show that SDEs
alone are entirely capable of generating protective CTL responses, which is dependent on crosspriming by BATF3+ DCs.
Cross-priming of CD8+ T cells is important for inducing antiviral CTL responses,
especially in settings where direct-presentation is not possible (e.g., APCs are not susceptible to
infection) or is evaded (e.g., impairing maturation of infected-APCs or inhibiting MHCI
presentation). Consistent with this notion, herein we showed that the induction of antiviral CTL
responses is dependent on cross-presentation in the presence of CPXV-mediated MHCI
inhibition. Priming of CD8+ T cell in the absence of viral MHCI inhibition during CPXV
infection was also dependent on cross-presenting BATF3+ DCs, albeit to a less extent. While we
have not ruled out the possibility that ΔMHCIi-infected BATF3+ DCs prime CTL precursors by
direct presentation, CPXV-infected DCs have reduced expression of costimulatory molecules
involved in T cell activation 94,95, suggesting that direct-presentation may be limited even in the
absence of CPXV012 and CPXV203. Nonetheless, there are clearly factors other than MHCI
inhibition that skew priming of T cells towards cross-priming and further study of CPXV ORFs
in the context of ΔMHCIi provides an excellent opportunity to investigate such factors. In this
study, we provide evidence that cross-priming is the main mechanism driving CPXV-specific
CTL responses.
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Our studies also indicate that cross-dressing plays no significant role in the T cell
response to CPXV infections in vivo. Cross-dressing has been proposed as a mechanism by
which APCs can rapidly acquire peptide epitopes for presentation to CTL precursors, thereby
eliminating the time spent for antigen processing 65,66. In support of this, DCs can be crossdressed in vitro by peptide-MHCI complexes from epithelial cells 96, which are commonly
targeted by viruses and thus may serve as a common source of preformed viral peptide-MHCI.
Moreover, peptide-MHCI from parenchymal cells cross-dressed DCs in vesicular stomatitis virus
(VSV)-infected mice and the cross-dressed DCs induced proliferation of memory CD8+ T cells,
but not naïve T cells. However, priming of naïve antigen-specific CD8+ T cells by cross-dressed
DCs can occur, as demonstrated using DNA vaccination and transfer of adenovirus infected DCs
66,67

. In contrast to these studies, we found that cross-dressing does not efficiently prime or drive

expansion of endogenous antigen-specific naïve and memory CD8+ T cells during CPXV
infection.
While previous reports on cross-dressing provide compelling evidence that cross-dressing
occurs in vivo, the transfer of TCR tg T cells in these studies may have resulted in nonphysiological induction of CD8+ T cells by cross-dressed DCs. Additionally, cross-dressing in
these experimental settings may have been promoted due to a potential generation of
supraphysiological levels of peptide-MHCI by DNA vaccination or by transfer of adenovirus
infected DCs. These factors may explain the difference between previous studies and our results
using CPXV infection. Because CPXV encodes an extensive arsenal of immunomodulatory
proteins, the possibility that CPXV directly or indirectly inhibits cross-dressing may also explain
these conflicting results. For example, downregulation of MHCI cell surface expression by
CPXV012 and CPXV203 may prevent transfer of peptide-loaded MHCI molecules by
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trogocytosis, a process in which intercellular exchange of intact membranes occurs during the
formation of an immunological synapse 97–100. If trogocytosis is required for cross-dressing of
APCs in vivo, as been demonstrated in vitro 65, then cross-dressing dependent T cell responses
are expected to be abrogated during CPXV infection. Ultimately, our results suggest that
antigens are acquired from necrotic/apoptotic bodies or secreted viral proteins found in the
extracellular milieu and are then predominantly cross-presented during CPXV infection.
Cross-presentation of peptide epitopes may also be influenced by the nature of the
antigens and can affect the extent of CD8+ T cell immunodominance 101–103. For instance, the
secreted immunodominant antigens of M. tuberculosis are likely processed through the crosspresentation pathway 104,105 and eliminating bacterial secretion prevents priming of IDE-specific
CD8+ T cells during M. tuberculosis infection 81. Priming of naïve CD8+ T cells against cellassociated subdominant SV40 large tumor antigen (T Ag) epitope V is also dependent on crosspresentation, but the response against the V epitope is limited because it is inefficiently crosspresented relative to the T Ag IDE 103. Our findings suggest that cross-presented CPXV IDEs can
be derived from cell-associated antigen since ablating B8 secretion did not negatively affect
cross-priming dependent induction of B819-26-specific CD8+ T cells. Moreover, cell-associated
B8 elicited a greater B819-26-specific CD8+ T cell response in comparison to secreted soluble B8,
which is consistent with the preferential in vivo cross-presentation previously reported for cellassociated antigens 83,84. However, the underlying mechanisms of immunodominance are
complex and are often context dependent as we found that secretion of CPXV B8 is not required
for immunodominance and that cross-presentation of CPXV SDEs in the absence of the
immunodominant B819-26 epitope stimulated a robust CTL response. The fact that the CTL
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response to SDEs compensated for the absence of B819-26 suggests that the SDE response is
suppressed by the B819-26 response, supporting the concept of immunodomination.
In many cases immunodomination occurs as a consequence of T cell competition for
limiting APC resources 90,92,106,107. For instance, competition for peptide-MHCI complexes on
APCs during primary CTL responses can occur as a result of antigen abundance 108. In support of
this, we showed that concurrently increasing subdominant antigen levels and reducing
immunodominant antigen levels allow SDEs to gain dominance during the primary response to
CPXV infection. Similarly, modulating the antigen abundance through different methods during
influenza A virus and VACV infection has been shown to influence immunodomination 55,109. In
certain models, immunodomination can be overcome when APCs present different epitopes
separately 91,100,107, indicating that CD8+ T cells of different specificities can cross-compete for
peptide-MHCI complexes on APCs. This has been convincingly demonstrated in models where
immunodomination occurs when APCs co-present model antigen epitopes. However, epitope copresentation by APCs does not always influence immunodomination, as we have shown here for
primary responses, and the role of cross-competition in inducing antiviral CTL responses is
controversial 110.
We found that cross-competition for peptide-MHCI complexes is relevant and that
immunodomination occurs during secondary responses as a consequence. Alternatively, the
suppressed B819-26 response in our cross-competition experiments may have resulted from K3615-specific

memory CD8+ T cells killing the BMDCs that were pulsed with B819-26 and K3L6-15 at

the same time. Nevertheless, we observed partial rescue of the B819-26 response when the
epitopes were separated on BMDCs. This partial rescue may be due to peptide exchange between
BMDCs that were pulsed separately and adoptively transferred as a mix, which would
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subsequently result in epitope co-presentation and K36-15-specific memory CD8+ T cell
immunodomination. However, additional factors that we did not test such as cross-competition
for growth factors, antigen-specific T cell precursor frequencies, or TCR avidity 111 likely
contribute to the memory T cell immunodomination as well.
Remarkably, immunodomination during the secondary response against CPXV was
exerted by SDE-specific memory CD8+ T cell. The capacity for SDE-specific memory CD8+ T
cells to inhibit the response to an IDE has been shown with influenza virus 54, but prior priming
with SDE peptides did not result in memory CD8+ T cell immunodomination using VACV, as
shown by Wang et al 56. Here in our study, memory CD8+ T cell immunodomination was clearly
evident when SDE-primed mice were challenged with WT CPXV, whereby the naïve B819-26specific CD8+ T cell response was suppressed. Moreover, memory CD8+ T cell
immunodomination was not affected by MHCI inhibition. However, mice were primed by CPXV
infection (in this study) as opposed to individual SDE peptides (as done by Wang et al). These
experimental differences suggest that the priming stimulus and the breadth of the primary
response influences immunodomination during secondary responses against poxviruses.
Taken together, our findings highlight the need to consider the effects of pre-existing
immunity on the outcome of secondary responses and vaccinations. An advantage to using
VACV-based vaccines is that in addition to providing protection against heterologous pathogens,
the native vector epitopes (both IDEs and SDEs) can provide cross-protection against related
orthopoxviruses, as supported by our findings here and previous reports 112–115. However, as a
consequence of pre-existing immunity, memory CD8+ T cell immunodomination may limit the
target antigen response following immunization with VACV-based vaccines, in turn resulting in
non-efficacious vaccinations. For example, native VACV epitopes can mask responses against
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target antigens expressed by VACV vaccine vectors 74. Nevertheless, our results support the
ongoing evaluation for poxviruses as promising vaccine vectors, and stress the necessity to
develop novel vaccination strategies.

Materials and Methods
Cell lines, mice and viruses.
Cell lines HeLa, Vero, and P815 were obtained from the American Type Culture Collection
(ATCC). DC2.4 cells were a kind gift from Dr. Kenneth Rock, University of Massachusetts
Medical School. HeLa, Vero, DC2.4, and P815 cells were cultured respectively in Dulbecco’s
Modified Eagle Medium (DMEM), Minimum Essential Medium (MEM) or RPMI supplemented
with 10% FBS (Mediatech), 100 U/ml penicillin, 100 g/ml streptomycin, 1mM sodium pyruvate,
and non-essential amino acids (Gibco). VACV-WR was obtained from the ATCC. MCMV
Smith strain was a gift from Dr. Herbert Virgin, Washington University. CPXV BAC pBR miniF construct was kindly provided by Dr. Karsten Tischer, Free University of Berlin. Mutant
viruses were generated by en passant mutagenesis
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using primers listed in S2.1 Table. Gene

fragments were synthesized (Integrated DNA Technologies) and assembled using Gibson
Assembly (New England BioLabs) for cloning of the B8-mCherry fusion contructs (S2.2 Table).
Infectious BAC-derived viruses (S2.3 Table) were reconstituted using a slightly modified
method previously described by Xu et al
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. In brief, ~8x105 Vero cells seeded in 6-well plates

were infected with fowlpox virus (FWPV) at an MOI of 1. Transfection of FWPV-infected Vero
cells was carried out 1 hour post-infection (hpi) with 4 µg of BAC DNA and 5 µL of
Lipofectamine 2000 transfection reagent (ThermoFisher Scientific) according to the
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manufacturer’s instruction. Serial dilutions of reconstituted infectious virus were passaged up to
four times on Vero cells in order to remove the mini-F vector sequence. Wells harbouring single
GFP-negative plaque were isolated and used for preparing virus stocks as previously described
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. C57BL/6Ncr mice were purchased from the National Cancer Institute. B6.129S2-Ighmtm1Cgn/J

mice were purchased from the Jackson Laboratory. Batf3-/- mice crossed to the C57BL/6 and
BALB/c background were kindly provided by Dr. Kenneth Murphy, Washington University.
Growth curves were performed on Vero cells. Supernatant and cells were harvested at 12, 24, 28,
and 72 hpi and viral titers were determined by plaque assay using Vero cells.

Peptide binding Assay
TAP2-deficient RMA-S (H-2b) cells were cultured overnight at 28°C in 5% CO2 to accumulate
peptide-receptive MHCI molecules at the cell surface. Peptides were then added at various
concentrations and the cells were transferred to 37°C. After 6 h of incubation at 37°C, cells were
harvested and washed twice in PBS. H-2Kb cell surface expression was then measured by flow
cytometry.

Western blot
1 x 106 HeLa cells were infected at a MOI of 5. Cells and supernant were collected at 4 hpi and
were lysed on ice for 5 min in RIPA lysis buffer supplemented with 1x Halt protease and
phosphatase inhibitor cocktail. Cells were further processed for subcellular fractionation using a
Subcellular Protein Fractionation Kit (ThermoFisher). Samples were mixed with Laemmli
sample buffer (Bio-Rad), incubated at 95°C for 5 minutes, separated by SDS-PAGE, and
transferred to PVDF membranes. Immunoblotting was performed using rabbit polyclonal anti35

mCherry and rabbit monoclonal anti-EGFR (Abcam) followed by horseradish peroxidase (HRP)conjugated goat anti-rabbit IgG (Cell Signalling).

Generation of bone marrow chimeras
6 weeks of age Batf3-/--F1 (H2bxH2d) mice were depleted of NK cells by i.p. administration of
100 µg of PK136 antibody. Two days later, the mice were lethally irradiated with 950 rads and
were reconstituted with 1x107 T cell depleted C57BL/6, BALB/c, or a 1:1 mixture of BALB/cThy1.1 and Batf3-/--F1 bone marrow cells. Bone marrow chimeras were treated with antibiotics
for 4 weeks and were allowed to reconstitute for 8 weeks before use.

Generation of bone marrow-derived DCs and immunization
BM-derived dendritic cells (BMDCs) were generated by culturing BM cells in the presence of 20
ng/mL GM-CSF and IL-4 (PeproTech) for 8 days, as previously described
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. LPS (150ng/nL)

was then added and the cells were allowed to mature overnight. The cells were then pulsed with
peptide (1g/mL, 45 min). Cells were washed extensively in PBS and a total of 2.5 x 105 DCs was
injected intravenously (i.v.) into recipient mice.

Mouse infection and CD8+ T cell adoptive transfer
Mice were age- and sex-matched for each experiment and used at 8-10 weeks of age. Mice were
infected as previously described for i.n. and s.s. infections 31. For s.s. infections, fur was trimmed
with clippers, then a thin layer of Vaseline was applied over the trimmed region and the
remaining fur was shaved over with a double-edge razor blade one day before infection. Mice
infected by i.p. or s.c. administration were injected with a volume of 100µL or 200µL of virus
36

inoculum per mouse, respectively. For co-infection experiments, splenocytes isolated from B6
mice were infected at an MOI of 5, harvested 1 hpi, and washed three times with PBS. 1 x 105
infected cells in 200 µL of PBS were transferred intravenously into naïve B6 mice. For the
CPXV SDE protection experiment, CD8+ T cells from splenocytes of infected B6 mice that had
been infected 7 days earlier with WT CPXV or MCMV were isolated by positive selection using
anti CD8a MicroBeads (Miltenyi Biotec). 3 x 106 CD8+ T cells were transferred intravenously
into naïve B6 mice. Mice were infected approximately 24 h after transfer.

Flow cytometry, IFN-γ production assays, and antibodies
Single-cell suspensions from the lungs and spleens were prepared at the indicated days postinfection as previously described
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. 1x106 cells were seeded in 96-well plates and were re-

stimulated with peptides or with 1x105 DC2.4 cells that had been infected for 4 h with ΔMHCI-i
or ΔMHCI-iΔB8 CPXV (MOI 5). Cells were incubated at 37°C, 5% CO2. After 1 h at 37°C,
GolgiPlug (BD Biosciences) was added to each well. Three hours later, cells were stained on ice
with Fixable Viability Dye eFlour 506 (eBioscience) before staining of cell surfaces for the
indicated surface markers. Cells were then fixed/permeabilized and stained for IFN-γ.
Background levels were determined using cells from uninfected mice, which usually ranged
between 0.01-0.05%, and were subtracted from the values presented. For intracellular staining of
GzmB and tetramer staining, cells were stained ex vivo without stimulation and without
incubation

with

GolgiPlug.

H-2Kb-TSYKFESV

tetramers

were

produced

in

the

Immunomonitoring Laboratory within the Center for Human Immunology and Immunotherapy
Programs (Washington University). The following monoclonal antibodies were obtained from
ThermoFisher, BD Biosciences or eBioscience: CD3 (145-2C11), CD8α (53-6.7), CD8β
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(eBioH35-17.2), CD4 (RM4-5), CD44 (IM7), CD62L (MEL-14), GzmB (GB12), KLRG1 (2F1),
CD127 (A7R34) and IFN-γ (XMG1.2).

Statistics
The data are shown as mean ± SEM and were analysed with an unpaired Student t test or oneway ANOVA followed by Tukey posttest comparison using Prism GraphPad software, asterisks
indicate statistical significance and the p values are denoted as *p<0.05, **p<0.01, ***p<0.001.
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Figures and Tables

Fig 2.1 Secretion of the immunodominant antigen is not required for immunodominance
(A) Schematic representation of the B8-mCherry fusion proteins; the location of the signal
peptide, GGSGGS linker, TMD, and mCherry are depicted. (B) B8TMmC is not secreted. HeLa
cells were infected at an MOI of 5 with B8TMmC or B8MC. Cells and supernatant were
harvested at 4 hpi for subcellular fractionation and mCherry and EGFR expression was
determined by western blot; equal loading and transfer of samples was confirmed with ponceau S
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red (P-Red) staining. CE = cytoplasmic extract; ME = membrane extract; SN = supernatant. Data
are representative of two independent experiments. (C, D) Comparable CTL priming by
B8TMmC and B8mC. CD8+ T cell responses in the spleen of B6 (n = 5) i.n. infected with 5 x
103 pfu (C) and 1.5 x 104 pfu (D) B8TMmC or B8mC were determined by ex vivo restimulation
with CPXV peptides and ICS at 8 dpi. Data are representative of two independent experiments.
(E) Cell-associated antigen is cross-presented more efficiently than soluble antigen. B8-specific
CD8+ T cell responses in the spleen of B6 (n = 5) i.n. infected with 1.5 x 105 pfu B8TMmC or
B8mC were determined by tetramer staining at 8, 9, and 10 dpi. Data are representative of two
independent experiments. (F) CD8+ T cell responses require BATF3+ DCs. B6 and Batf3-/- mice
(n = 7-10) were i.n. infected with 5 x 103 pfu B8TMmC or B8mC and the B8-specific CD8+ T
cell responses in the spleen were determined at 6 dpi. n = 3 mock-infected mice. Data are the
combined results of three independent experiments.
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Fig 2.2 Cross-priming induces CTL responses during CPXV infection. (A) BATF3+ DCs
cross-prime CPXV-specific CTL precursors. B6 or Batf3-/- mice (n = 6) were infected i.p. with 1
x 105 pfu WT CPXV, ΔMHCIi, or VACV-WR, and CD8+ T cell responses were measured by ex
vivo restimulation with infected DC2.4 cells and ICS at 8 dpi. The data are the combined results
of three independent experiments. (B) Induction of VACV-specific CTLs is not dependent
BATF3+ DCs. B6 or Batf3-/- mice (n = 6-7) were infected i.p. with 1 x 105 pfu VACV-WR and
CD8+ T cell responses in the spleen were measured at 6 dpi. The data are the combined results of
two independent experiments.
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Fig 2.3 Conventional cross-priming, but not cross-dressing, is the main mechanism driving
CTL responses during CPXV infection. (A) Schematic of BMC cross-dressing experiment. B)
CTLs are not activated by cross-dressed APCs. Batf3-/- -F1 mice (n = 5-6) were depleted of NK
cells, lethally irradiated 2 days after NK cell depletion, and reconstituted with 1 x 107 T cell
depleted BM cells from B6 or BALB/c mice. 8 weeks later, chimeric mice were infected i.n. with
5 x 103 pfu WT CPXV and CD8+ T cell responses in the lungs were determined by ICS at 8 dpi.
(C) Memory CTLs are not activated by cross-dressed APCs. Chimeric mice (n = 3-5) previously
infected for 25 days were challenged with 5 x 104 pfu WT CPXV and CD8+ T cell responses in
the lungs were determined by ICS at 8 days after challenge. The data are the combined results of
three independent experiments.
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Fig 2.4 Cryptic subdominant epitopes can compensate for the loss of the CPXV
immunodominant epitope-specific CTL response, revealing immunodomination. CTL
immunodomination occurs during primary responses against CPXV. (A and B) B6 mice (n = 1113) were infected i.n with 5 x 103 pfu of WT, ΔB819-26, ΔMHCIi, or ΔMHCIiΔB819-26 and were
sacrificed at 8dpi. CD8+ T cells in the lungs were restimulated with B819-26 peptide or DC2.4
cells infected with ΔMHCIi or ΔMHCIiΔB819-26. The legend to B indicates the viruses used for
infections and the X-axis indicates the stimuli used for ex vivo restimulation and ICS. Data are
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the combined results of five independent experiments. (C) WT and mutant viral strains replicate
to similar titers. Viral titers in the lungs of infected B6 mice were determined at 8 dpi by plaque
assay. (D) Comparable CTL responses against all viral strains tested. B6 mice (n = 6) were
infected by i.p. and splenic CD8+ T cells were restimulated with peptides or (E) with DC2.4 cells
infected with ΔMHCIi or ΔMHCIiΔB819-26. Data are the combined results of four independent
experiments.

45

46

Fig 2.5 CPXV subdominant epitope-specific memory CTLs immunodominate responses by
naïve CD8+ T cells. (A) Schematic of i.n. prime/boost experiment. (B and C)
Immunodomination of naïve CD8+ T cells. B6 mice (n = 5-6) were primed i.n. with 5 x 103 pfu,
i.n. boosted at 25 dpi with 5 x 103 pfu (B) or 5 x 104 pfu (C), and sacrificed 8 days after boosting.
CD8+ T cell responses in the lungs (top) and spleens (bottom) were determined by ICS. Data are
the combined results from two independent experiments. (D) Generation of memory CD8+ T
cells. i.n. primed mice were sacrificed at 25 dpi and memory CD8+ T cells were measured in the
spleen by ICS. (E) Antibody-independent memory CTL immunodomination. µmT mice were
primed by s.s. with 1 x 105 and i.n. boosted with 1 x 105 pfu at 25 dpi. CD8+ T cell responses in
the spleens were determined 7 days after boost. Data are the combined results from two
independent experiments. (F) Memory CTLs cross-compete for peptide-MHCI complexes on
APCs. Peptide-pulsed DCs were adoptively transferred by tail vein injection into ΔB819-26primed B6 mice (n = 4) and CD8+ T cell responses in the spleen were evaluated by ICS 6 days
after transfer. (G) Naïve CD8+ T cells do not cross-compete for peptide-MHCI complexes on
APCs. Peptide-pulsed BMDCs were transferred into naïve B6 mice and CD8+ T cell responses
were evaluated by ICS as in the experimental setup of F. Data are representative of two
independent experiments.
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Fig 2.6 CPXV subdominant epitopes gain dominance when the relative abundance of
subdominant antigens is increased during primary responses. (A) Schematic of co-infection
experiment. Splenocytes were harvested from B6 mice and infected at an MOI of 5 with WT
CPXV and ΔB819-26 separately or mock-infected. At 1 hpi, infected cells were mixed at different
ratios and a total of 1 x 105 infected cells were administered into naïve B6 mice (n = 5-6) by tail
vein injection. (B) A role for antigen levels in CTL immunodomination. Mice were sacrificed at
7 dpi and splenic CD8+ T cells were restimulated with B8 peptide or (C) with DC2.4 cells
infected with ΔMHCIi. Data are the combined results from two independent experiments.
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Fig 2.7 Subdominant epitope-specific CTL responses protect against CPXV infection. (A)
Schematic of adoptive transfer experiment. B6 mice were primed with ΔB819-26 or MCMV by
s.c. and i.p. routes, respectively. At 7 dpi, splenic CD8+ T cells were isolated by positive
selection and adoptively transferred into naive B6 mice (n = 11-13) by tail vein injection. After
~1 day, mice were infected by i.n. inoculation with ΔB819-26 or ΔMHCIiΔB819-26 and monitored
for survival (B) and weight loss (C). Data are the combined results from two independent
experiments.

49

S2.1 Fig. Cross-dressing by hematopoietic cells does not induce CTL responses during
CPXV infection. (A) Schematic of BMC cross-dressing experiment.
(B) Hematopoietic cells do not contribute to CTL-priming via cross-dressing of APCs. Lethally
irradiated Batf3-/- -F1 mice (n = 8) reconstituted with a 1:1 mixture of BALB/c-Thy1.1 and Batf3/-

-F1 bone BM cells were infected i.p. with 1 x 105 pfu WT CPXV and assessed as in the

experimental setup in Fig 3. n = 4 WT-F1 CPXV-infected mice. The data are the combined
results of three independent experiments.
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S2.2 Fig. Mutating the CPXV immunodominant CD8+ T cell epitope anchor residues alters
peptide binding affinity to MHCI H-2Kb, but does not affect CPXV replication and
virulence. Peptide binding assays were performed using RMA-S cells. (A) Peptide anchor
residues are critical for H-2Kb binding. Cell surface staining of H-2Kb after incubation with
peptide (black) or without peptide (red) are shown; isotype control staining is shown in grey.
Data are representative of three independent experiments. (B) B8 mutations do not affect viral
kinetics in vitro. Vero cells were infected at an MOI of 0.01 for multi-step growth curves. Data
are the combined results of three independent experiments performed in duplicates. (C) B8
mutations do not affect viral pathogenesis in vivo. B6 mice (n = 5-9) were infected i.n. with 4 x
104 pfu of the indicated viruses and monitored for survival and weight loss.
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S2.3 Fig. Cross-priming of cryptic subdominant epitopes can compensate for the loss of the
CPXV immunodominant epitope-specific CTL response.
Peptide anchor residues are critical for inducing B8-specific CTL responses. (A and B) B6 mice
(n = 10) were infected i.n with 5 x 103 pfu WT, ΔB819-26, ΔMHCIi, or ΔMHCIiΔB819-26 and were
sacrificed at 8dpi. The B8-specific CTL response was evaluated by tetramer staining. Data are
the combined results from two independent experiments. (C and D) Comparable CTL responses
against all viral strains. B6 mice (n = 5) were infected and sacrificed at 8 dpi as in experimental
setup of A and B. Cell surface expression of CD62L, CD44 and intracellular GzmB was
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determined for CD8+ T cells in the lungs. Data are representative of three independent
experiments. (E) BATF3+ DCs cross-prime SDE-specific CTL precursors. B6 or Batf3-/- mice (n
= 7) were infected i.p. with 1 x 105 pfu ΔB819-26 and CD8+ T cell responses were measured by ex
vivo restimulation with ΔMHCIiΔB819-26-infected DC2.4 cells and ICS at 8 dpi. Data are the
combined results from two independent experiments.
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S2.4 Fig. Viral MHCI inhibition does not affect the generation of memory CD8+ T cells
(A and B) Generation of memory CD8+ T cells following CPXV infection. B6 mice (n = 7) were
primed i.n. with 5 x 103 pfu WT or ΔMHCIi and were sacrificed at 25 dpi. Cell surface
expression of memory T cell markers (CD62L, CD44, KLRG1, and CD127) was determined for
TET+ CD8 T cells in the spleen. Data are the combined results from two independent
experiments.
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S2.5 Fig. CPXV-immunized mice survive lethal challenge in the absence of memory CD8+ T
cells
(A) Schematic of immunization and challenge experiment. B6 mice (n= 6-7) were primed i.n.
with 5 x 103 pfu of CPXV and lethally challenged at 25 dpi. Anti-CD8α or isotype control
antibodies were administered at the indicated times. (B) Complete depletion of CD8+ T cells.
The efficiency of antibody-mediated CD8 depletion was determined one day after the first
administration of antibodies. (C) CPXV immunized mice generate protective antibody responses.
Challenged mice were monitored for survival and weight loss.
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S2.1 Table. Primer sequences.

S2.2 Table. Synthesized gene fragments.

S2.3 Table. Viruses used in this study.
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Chapter 3:
Viral MHCI inhibition evades tissue-resident
memory CD8+ T cell (TRM) responses, but not
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Abstract
Tissue-resident memory CD8+ T cells (TRM) confer rapid protection and immunity against viral
infections. Many viruses have evolved mechanisms to inhibit MHCI presentation in order to
evade cytotoxic CD8+ T cells (CTLs), suggesting that these mechanisms may also apply to TRMmediated protection. However, the effects of viral MHCI inhibition on the function and
generation of TRM is unclear. We show that viral MHCI inhibition dampens immunodominance
within the lung TRM pool, indicating an effect on the TRM repertoire, but this effect is not elicited
in the skin. Unexpectedly, local cognate antigen enhances CD8+ TRM development even in the
occurrence of viral MHCI inhibition and CTL evasion. However, local cognate antigen is not
required for CD8+ TRM maintenance. We also show that viral MHCI inhibition efficiently evades
CD8+ TRM effector functions. Our findings suggest that the T cell receptor (TCR) signaling
threshold for CTL-mediated cytotoxicity and TRM activation may be higher than the threshold for
antigen-driven differentiation of CTLs to TRM.
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Introduction
Cytotoxic CD8+ T cells (CTLs) mediate potent immunity against viral infections and
respond to foreign antigens presented by major histocompatibility complex I (MHCI) molecules
59–61

. The importance of MHCI antigen presentation is underscored by the fact that viruses have

evolved strategies to obstruct MHCI presentation. For instance MHCI inhibition by cowpox
virus (CPXV) evades CTL responses during primary infections, and the absence of the
endogenous MHCI inhibitors CPXV012 and CPXV203 significantly attenuates CPXV in a CTLdependent manner 31,36,52. Moreover, the ability to inhibit MHCI presentation appears to be an
evolutionarily conserved feature among cytomegaloviruses (CMVs) and other viruses. Viral
MHCI inhibition evades CTL responses against murine CMV (MCMV) infection in the salivary
glands (SGs) of naïve hosts and is critical in allowing for rhesus CMV (RhCMV) superinfection
of hosts harboring memory CD8+ T cells 72,119. However, tissue-resident memory CD8+ T cells
(TRM) are able to protect against local infection when MCMV is directly introduced into the SGs,
likely due to an early viral tropism for cells refractory to viral MHCI inhibition 120. Therefore,
the affects of viral MHCI inhibition on CD8+ TRM responses remain unclear.
CD8+ TRM typically form in non-lymphoid tissues following viral infection and are a noncirculating subset of memory T cells, whereas the effector memory T cell (TEM) and central
memory T cell (TCM) subsets continuously recirculate 121. Because CD8+ TRM primarily develop
and remain at common sites of pathogen entry, they are considered a front-line defense against
secondary or recurrent peripheral infections; both CD8+ and CD4+ TRM promote viral control and
survival against lethal infection, mediate cross-strain protection, and can even provide better
protection than the circulating TRM counterparts 122–127.
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The factors driving TRM development have implications for tissue-specific vaccine
strategies. For example, the ‘prime and pull’ strategy demonstrates that CTLs can be recruited to
the skin or vagina in an antigen-independent manner and drive TRM formation, resulting in longterm immunity against local challenge 124,128. Conversely, recruitment or inflammation alone
does not generate TRM in the lungs unless local cognate antigen is present 129,130, indicating
tissue-specific requirements for local cognate antigen during TRM differentiation. Depots of
persisting viral antigens in the lung may also affect the maintenance of memory T cells 131,132.
However, it is unknown whether persistent antigen presentation occurs in the skin or if MHCI
complexes are important for the maintenance of endogenous skin CD8+ TRM. In the context of
viral infections, local cognate antigen recognition promotes the formation of CD8+ TRM in the
skin, and is required for CD8+ TRM formation in the central nervous system, peripheral nervous
system, and the lungs 124,133–136.
These findings on the potential role of local antigen during viral infection raise an
interesting question: can viral MHCI inhibition affect local antigen recognition and reduce CD8+
TRM formation? To investigate this issue, here we compared CD8+ TRM formation and protection
following local infection with CPXV, which effectively downregulates MHCI and evades CTLs
in vivo 31,36,52,53, and a CPXV mutant lacking the capacity to inhibit MHCI presentation.
Surprisingly, viral MHCI inhibition affected CD4+ TRM formation, but not CD8+ TRM formation,
in the skin. We found that local secondary antigenic stimulation promoted CD8+ TRM formation,
despite CPXV-mediated MHCI inhibition and CTL evasion. After TRM differentiation, local
cognate antigen presentation was dispensable for TRM maintenance, but was critical by infected
cells to induce protective CD8+ TRM responses.
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Results
Viral MHCI inhibition affects the formation of CD4+ TRM, but not CD8+ TRM
CPXV mediates MHCI inhibition, which likely results in lower levels of local antigenic
stimulation of virus-specific CTLs by infected cells. Because local antigenic stimulation
enhances CD8+ TRM formation during vaccinia virus (VACV) skin infection 133, we hypothesized
that CD8+ TRM formation would be diminished in CPXV-infected skin. To test this, we infected
mice by skin scarification (s.s.) with WT or Δ12Δ203-CPXV and performed kinetic analyses of
CD8+ T cells that recognize the immunodominant H-2Kb-restricted epitope B819-26. Infection
with both viruses resulted in robust expansion and recruitment of B819-26-specific CD8+ T cells to
the skin at 1 week post-infection, which reduced in numbers approximately ~12 fold by 3 weeks
post-infection (Fig 3.1A). Nonetheless, B819-26-specific CD8+ T cells were still detectable in the
skin and the spleens of previously infected mice long after clearance of the infection (Fig 3.1, A
to D); CPXV skin infections are highly localized and are cleared within 1-2 weeks post-infection
31

. Mice infected with WT CPXV had a higher relative abundance of B819-26-specific CD8+ T

cells in the skin at 7 days post-infection (dpi) in comparison to Δ12Δ203-infected mice (Fig 3.1,
C and D), but there were no significant differences in absolute numbers in the skin for all
assessed time points.
Analysis of B819-26-specific CD8+ T cells during the memory phase showed that they
were predominantly located in the previously infected skin flank relative to the uninfected
contralateral flank (Fig 3.1B). These findings are consistent with previous reports 122,133,134. We
show that these cells expressed high levels of the TRM markers CD103 and CD69 than the B81926-specific

CD8+ T cells in the spleen (Fig 3.1, E and F), suggesting that CPXV s.s. infection
63

generates authentic CD8+ TRM. To verify tissue-residency of CD103+CD69+CD8+ cells, we
performed parabiosis between CD45.1+ naïve mice and CD45.2+ mice previously infected with
CPXV, referred to as naïve and memory mice respectively (Fig 3.1G). Comparison of the
CD103+CD69+CD8+ TRM in the skin of naïve and memory parabionts revealed the presence of
these cells in only the memory parabionts, showing that they are unable to circulate and are
indeed a resident population (Fig 3.1, H and I). Furthermore, B819-26-tetramer+ cells in the
spleens equilibrated between memory and naïve parabionts, but B819-26-tetramer+ TRM in the skin
were only present in memory parabionts (Fig 3.1, J to K). Regarding CD4+ TRM, CPXV s.s.
generated CD103+CD69+CD4+ T cells in the skin in comparable numbers to CD8+ TRM, and
parabiosis revealed that these cells were bona fide skin-resident CD4+ T cells (Fig S3.1, A to C).
Interestingly, we found that viral MHCI inhibition significantly reduced the abundance of these
CD103+CD69+CD4+ T cells in the skin (Fig S3.1, A and B). Taken together, these results reveal
that viral MHCI inhibition does not affect the overall development of CD8+ TRM, but does impair
the formation of CD4+ TRM in the skin.
CD4+ T cell help is critical for the local development of lung CD8+ TRM 137, but is
dispensable for the formation of CD8+ TRM in the female reproductive tract 138. To test the role of
CD4+ T cell help in the development of CD8+ TRM in the skin, we depleted CD4+ T cells by
injecting depleting antibodies 1 day before infection, and 2 and 5 dpi. This approach eliminates
CD4+ T cells during acute infection, but allows for their recovery by 30 dpi. CD4+ T cell help
was not required for priming of CD8+ T cells in the presence or absence of viral MHCI inhibition
(Fig S3.1, D and E). In accordance with our previous findings 31,52, we found that mice infected
with WT CPXV by s.s. succumbed to infection in the absence of CD4+ T cell help (Fig S3.1F),
despite the mounting an anti-CPXV CD8+ T cell response (Fig S3.1, E and F). These results
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underline the capacity of CPXV to efficiently evade CD8+ T cells and suggest that CD4+ T cell
help is required to control localized CPXV infection. In contrast, all mice infected with Δ12Δ203
CPXV survived in the absence of CD4+ T cell help (Fig S3.1F), which is also consistent with our
previous findings that CD8+ T cells alone are sufficient to control CPXV infection only in the
absence of viral MHCI inhibition 31,52. Given that Δ12Δ203 did not cause mortality, this
provided a setting to assess the role of CD4+ T cells in skin CD8+ TRM development. As
expected, depleting CD4+ T cells during the primary response reduced the overall number of
CD4+ T cells in the skin of mice previously infected with Δ12Δ203, but did not affect the overall
development of CD4+ TRM cells since the percentage of CD103+CD4+ T cells in the skin was
similar in isotype-control treated mice (Fig S3.1, G and H). However, it is possible that these
cells are not tissue-resident and that they may represent a different subset of CD4+ T cells.
Surprisingly, the formation of CD8+ TRM cells was augmented in the absence of CD4+ T cell help
(Fig S3.1, G to I), indicating that CD4+ T cell help is not required for the generation of skin
CD8+ TRM and may even hinder their development.

Viral MHCI inhibition dampens immunodominance within the lung CD8+ TRM population
We next assessed the effects of CPXV-mediated MHCI inhibition on lung CD8+ TRM
since the developmental requirements can differ substantially between certain tissue
microenvironments 135. In order to distinguish circulating memory CD8+ T cells from TRM we
performed in vivo intravascular (IV) staining 139. This method exclusively labels circulating and
intravascular lymphocytes (IV+ cells), but not tissue-associated lymphocytes (IV-). Within the
lung tissue, the overall proportions of IV-CD8+ T cells were equal in mice infected intranasally
(i.n.) with WT CPXV or Δ12Δ203 at 12 and 30 dpi, suggesting that viral MHCI inhibition also
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does not affect lung CD8+ TRM formation (Fig 3.2, A and B). However, higher proportions of IVB819-26-specific CD8+ T cells were found in the lungs following Δ12Δ203 infection compared to
WT CPXV infection (Fig 3.2C). This difference was also reflected in the spleen and blood at 30
dpi, despite equal proportions of B819-26-specific CD8+ T cells in the spleen and blood at 12 dpi
(Fig 3.2, D and E). Viral MHCI inhibition also significantly reduced the expression of CD103 on
IV- B819-26-specific CD8+ T cells at 12 dpi, but not CD69 expression (Fig 3.2, F and G). The
reduced expression of CD103 did not appear to affect CD8+ TRM development since IV- B819-26specific CD8+ T cells in the lungs of WT CPXV- and Δ12Δ203-infected mice expressed
comparable levels of CD69 and CD103 by 30 dpi (Fig 3.2, F and G). These data indicate that
viral MHCI inhibition reduces the immunodominance of the B819-26-specific cells within the
CD8+ TRM pool.

Local cognate antigen enhances CD8+ TRM cell formation, despite effective viral MHCI
inhibition and CTL evasion
Thus far, our results suggest that CD8+ TRM development is independent of local antigen
stimulation during CPXV infection. However, infection with WT CPXV is prolonged in
comparison to Δ12Δ203 infection 31, and it is therefore possible that during WT CPXV infection
continuous recruitment of CTLs may compensate for the decreased secondary antigenic
stimulation on TRM formation. To test if continuous recruitment of CTLs to the skin augments
CD8+ TRM formation in the presence of viral MHCI inhibition, we utilized the sphingosine 1phosphate receptor-1 (S1PR) agonist FTY720, which prevents lymphocyte egress from lymphoid
tissues. FTY720 treatment early during infection (1, 3, and 5 dpi) significantly reduced the
presence of circulating CD8+ T cells in the blood and the recruitment of CD8+ T cells to infected
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skin, but not priming of B819-26-specific CD8+ T cells in the inguinal lymph node (Fig S3.2, A to
C). We next performed co-infections of mice with WT CPXV and Δ12Δ203 on opposite flanks,
then blocked recruitment of CTLs starting at 7 days post-infection (dpi) with FTY720 treatment
(Fig S3.2D). If continuous recruitment of CTLs compensates for reduced secondary antigenic
stimulation, we expect that FTY720 treatment would reduce the abundance of CD8+ TRM in WT
CPXV-infected skin relative to Δ12Δ203-infected skin. While FTY720 significantly reduced the
presence of CD4+ and CD8+ T cells in the blood of co-infected mice, the relative abundance of
B819-26-specific CD8+ T cells at 9 dpi and CD8+ TRM cells at 40 dpi was not significantly
different in the WT CPXV and Δ12Δ203 infected skin, with or without FTY720 treatment (Fig
S3.2, E and F). These results indicate that CD8+ TRM develop without continuous recruitment of
CTLs.
Since CD8+ TRM development occurred despite viral MHCI inhibition, we tested if CD8+
TRM formation is independent of local antigen by performing co-infections, on opposite flanks,
with CPXV viruses that express either a WT (WT and Δ12Δ203-CPXV) or a variant of the
immunodominant B819-26 epitope (B8Y3AF5A and Δ12Δ203B8Y3AF5A) that is not presented
on MHCI 36 (Fig 3.3A). During the acute phase of infection, B819-26-specific CD8+ T cells had
modestly higher frequencies of CD69 expression in the skin where B819-26 was expressed in
comparison to the skin where the B819-26 epitope was absent, whereas CD103 expression was
unaffected (Fig S3.3, A and B). Nonetheless, a similar percentage and number of B819-26-specific
CD8+ T cells were recruited to both infected skin flanks in a local antigen-independent manner
(Fig 3.3B). This was also the case when co-infections were performed with Δ12Δ203 and
Δ12Δ203B8Y3AF5A. At 35 dpi, however, B819-26-specific CD8+ T cells were significantly
enriched in the skin where B819-26 was locally expressed as compared to infection where B819-26
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was locally absent (Fig 3.3C), even in the presence of CPXV-mediated MHCI inhibition.
Furthermore, the abundance of total CD8+ TRM was equal on both flanks of co-infected mice (Fig
3.3D), suggesting that TRM formation was only affected for B819-26-specific CD8+ T cells. Taken
together, these data indicate that local antigen does promote CD8+ TRM formation during CPXV
infection, regardless of viral MHCI inhibition.

Viral MHCI inhibition decreases CTL effector function, but not recognition of local
cognate antigen
We previously demonstrated that CPXV-mediated MHCI inhibition prevents CPXVspecific CTLs from recognizing infected cells 31,36,53. Consistent with our previous findings,
CTLs from CPXV-infected mice did not produce IFN-γ when co-cultured with WT CPXVinfected DC2.4 cells (Fig 3.4A). This effect was dependent on CPXV012 and CPXV203 as
CTLs co-cultured with Δ12Δ203-infected DC2.4 cells produced significantly higher levels of
IFN-γ and upregulated expression of Nur77 (Fig 3.4A), a transcription factor that is specifically
induced upon TCR engagement 140, as compared to WT CPXV-infected cells. However, our
results suggest that CPXV-specific CTLs can receive antigenic stimulation at the site of infection
in vivo (Fig 3.3).
To test if our in vitro findings extend to in vivo infection, we co-infected IFN-γ.Thy1.1
knockin reporter mice with WT and Δ12Δ203 CPXV on opposite flanks. Similar to our previous
findings 31, CPXV s.s. resulted in significantly higher frequencies of IFN-γ-producing CD8+ T
cells in Δ12Δ203-infected skin in comparison to WT CPXV-infected skin (Fig 3.4B).
Conversely, the frequency of Nur77+CD8+ T cells was not significantly different. We also found
similar results following co-infection of Nur77 GFP reporter mice (Fig S3.3C). In accordance
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with our findings that local cognate antigen promotes TRM formation (Fig 3.3C), these findings
suggest that CTLs recruited to CPXV-infected skin receive local cognate antigen stimulation,
despite viral MHCI inhibition and efficient CTL evasion by CPXV.
To identify the cells that could display local cognate antigen, we assessed CPXV tropism
in the skin of mice infected by CPXV s.s. There was significant recruitment of leukocytes in the
skin at 6 dpi (Fig 3.4C). The majority of infected cells were MHCII/CD45 double positive and
comprised of mainly CD11b+ dendritic cells (DCs) and monocyte-derived DCs (moDCs) (Fig
3.4, D and E). Moreover, CPXV+ and MHCII+ cells were found in close proximity to CD8+ cells
(Fig 3.4F), suggesting that CTLs may likely engage infected CD11b+ DCs or moDCs at the site
of infection; though viral MHCI inhibition should prevent virus-specific T cell stimulation.
Strikingly, CD103+ DCs were largely uninfected (Fig 3.4E), but were also found in close
proximity to CD8+ cells at the site of infection (Fig 3.4F), suggesting CTLs in the skin may be
engaging cross-presenting cells that are also involved in priming of naïve CPXV-specific CTL
precursors 31,36

CD8+ TRM in the skin persist in the absence of cognate antigen stimulation
Having established the importance of local cognate antigen in CD8+ TRM formation
against CPXV, we questioned whether local cognate antigen plays a role after CD8+ TRM
populations are established. To address this, we generated B2mfl/flRS26-Cre-ERT2 mice in which
tamoxifen treatment ablates MHCI expression. B2mfl/flRS26-Cre-ERT2 mice infected by s.s. were
treated with tamoxifen at 49 dpi and CD8+ TRM were analyzed in the skin approximately one
month after treatment (Fig 3.5A). Tamoxifen treatment eliminated expression of MHCI on
CD45+ cells from the skin and spleen of B2mfl/flRS26-Cre-ERT2 mice (Fig 3.5B), but not from
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tamoxifen treated B2mfl/fl littermate controls. We detected B819-26-specific TRM at comparable
levels in the skin of tamoxifen-treated B2mfl/flRS26-Cre-ERT2 and B2mfl/fl mice (Fig 3.5C),
indicating that persistent antigen presentation is not required for CD8+ TRM maintenance. This
was also observed for total CD8+ TRM in the skin (Fig 3.5D). Furthermore, we assessed TCR
engagement on CD8+ TRM using the Nur77 GFP reporter mice and found that CD8+ TRM are
Nur77-negative (Fig 3.5E). Therefore, CD8+ TRM do not receive cognate antigen stimulation in
the skin and are maintained in an antigen-independent manner.

Viral MHCI inhibition evades local CD8+ TRM responses
Since viral MHCI inhibition evades CTL responses during primary CPXV infection, we
next sought to investigate the effects of viral MHCI inhibition on CD8+ TRM effector function in
the absence of other anti-CPXV immune responses. To do so we generated a recombinant
influenza virus that expresses the CPXV B819-26 epitope (Flu-B8) and infected mice by the i.n
route. This resulted in the formation of B819-26 -specific TRM in the lungs of infected mice at 30
dpi (Fig S3.4). We next challenged the mice with CPXV at 30 dpi (Fig 3.6A). To prevent
circulating memory CD8+ T cells from contributing to viral control upon CPXV challenge, we
treated Flu-B8-infected mice with FTY720 throughout the course of the CPXV challenge. Viral
titers in the lungs of mice challenged with Δ12Δ203 were significantly lower than in mice
challenged with WT CPXV (Fig 3.6B), demonstrating that viral MHCI inhibition reduces
protective CD8+ TRM responses in the lungs. CD8+ TRM-mediated protection was antigendependent since challenge with B8 deficient viruses resulted in titers comparable to challenge
with WT CPXV.
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To test if these findings also hold true during CPXV skin infection, we used µMT mice,
which lack mature B cells, in order to avoid humoral responses against CPXV challenge. µMT
mice previously infected by s.s. with Δ12Δ203 harbored few B819-26 -specific CD8+ TRM in the
skin (Fig S3.5), which is consistent with the findings that infection of µMT mice generates
significantly lower numbers of memory CD8+ T cells in comparison to infection of WT C57BL/6
mice 141,142. We next tested whether depleting CD4+ T cells during acute infection of µMT mice
would increase CD8+ TRM formation. Similar to what we observed in WT C57BL/6 mice (Fig
S3.1, G to I), depleting CD4+ T cells significantly increased CD8+ TRM formation in the skin of
µMT mice infected by s.s., but not i.n. infection (Fig S3.5). In contrast, depleting CD4+ T cells
did not significantly increase the number of B819-26 -specific CD8+ T cells in the spleen of µMT
mice previously infected by s.s. at 30 dpi.
Based on these findings, we induced CD8+ TRM formation in CD4+ T cell-depleted µMT
mice by s.s. with Δ12Δ203 and subsequently challenged the skin with WT CPXV and Δ12Δ203
at 30dpi (Fig 3.6C). Viral titers in the skin of naïve mice were not significantly different in WT
CPXV and Δ12Δ203-infected lesions 4 days after challenge (Fig 3.6D). Similarly, viral titers
were not significantly different in previously infected µMT mice lacking skin CD8+ TRM (i.n.
infected). Conversely, viral titers and scab formation in the Δ12Δ203 lesions of µMT mice
harboring skin CD8+ TRM (s.s. infected) were significantly reduced (Fig 3.6D). WT CPXV titers
were also reduced in mice immunized by s.s., although the difference was not statistically
significant. It is possible that CD8+ TRM activation by Δ12Δ203-infected cells provoked an
antiviral state in surrounding areas, as previously demonstrated for skin CD8+ TRM 143, and
thereby protected against WT CPXV infection at adjacent sites. These data indicate that CD8+
TRM are protective against CPXV, but more so in the absence of viral MHCI inhibition.
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Interestingly, similar results were obtained in µMT mice treated with isotype control antibodies
(Fig 3.6E).

Discussion
In this study, we assessed the effects of viral MHCI inhibition on the generation and
function of TRM. While viral MHCI inhibition prevents CTL-mediated viral clearance, curiously
it does not appear to obstruct local antigenic stimulation of CTLs and subsequent CD8+ TRM
formation. Consistent with what was previously reported for VACV skin infection 133,134, local
antigenic stimulation promoted CD8+ TRM formation in CPXV-infected skin. Our findings
suggest that local antigenic stimulation of CTLs may promote CD8+ TRM development without
eliciting T cell-mediated cytotoxicity or cytokine production directed against infected cells.
Our findings also raise the possibility that TRM precursors receive local antigenic
stimulation from cross-presenting cells in situ 144,145. This possibility would explain why local
antigen stimulation enhances TRM formation that is not significantly affected by the presence of
viral MHCI inhibition. Since cross-presentation by BATF3+ DCs imprints TRM precursors in the
lymph nodes 146 and is required for CPXV-specific T cell priming 31,36, these cells are candidates
for being involved in local cross-presentation; further investigation will be needed to determine
their relative contribution to in situ cross-presentation on TRM development. Intriguingly, these
data also raise the possibility that local cross-presentation may be involved in the activation of
skin CD8+ TRM.
Local antigen presentation by APCs is critical for the activation of CD8+ TRM in the
female genital tract and CNS 136,147, but whether direct contact with infected target cells is
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required for CD8+ TRM functions is uncertain. For instance, in situ peptide stimulation of CD8+
TRM is sufficient to induce a tissue-wide antiviral state and protects against antigenically distinct
viruses 143,148. Therefore, CD8+ TRM activation and protection can ensue independently of direct
cell-cell contact with infected target cells. Conversely, we found that CD8+ TRM protection
during viral infection is abrogated by viral MHCI inhibition, suggesting that TCR/peptide-MHCI
(pMHCI) stimulation via engagement of infected target cells is needed for optimal CD8+ TRM
functions. Based on the in vivo effect of viral MHCI inhibition, we postulate that the level of
TCR stimulation needed to trigger CD8+ TRM and CTL effector functions is higher than the level
needed to promote local antigen-dependent TRM formation.
Additionally, TRM development and formation in the lungs of CPXV-infected mice
remained largely unaffected by viral MHCI inhibition, but viral MHCI inhibition dampened
immunodominance within the lung TRM pool. Immunodominance is not affected by CPXV012
and CPXV203 during primary CPXV infection 31,36, but the breadth and the levels of viral
epitopes presented in the context of viral MHCI inhibition can differ from the epitopes presented
in the absence of viral MHCI inhibition 57,85. As a consequence, increased antigen presentation
and antigen abundance during respiratory infection with Δ12Δ203 potentially promotes CTL
cross-competition for pMHCI complexes, which can affect the TRM repertoire 134,135. These
findings were not found following CPXV skin infection, suggesting that differences in the
microenvironment also contribute to the effects on TRM immunodominance. Moreover,
respiratory viral infections results in persistent antigen presentation 131,149,150, and can contribute
to the locality of memory T cells 151. Persistent antigen presentation was therefore an appealing
explanation for the long-term maintenance of TRM in peripheral tissues.
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Here we used inducible deletion of B2m to test if persistent stimulation is required for
maintaining TRM. We found that deletion of B2m after TRM formation did not affect the number
of TRM cells, suggesting that local cognate antigen, or even low-level stimulation from crossreactive pMHCI complexes is not required for TRM maintenance. However, since our studies
focused on the CD45+ compartment, it is possible that low-level expression of MHCI on nonhematopoietic cells could contribute to TRM maintenance. Nonetheless, our results add to
previous reports 124,128,152–154 by suggesting that TRM maintenance is also apparently independent
of cross-reactive pMHCI complexes.
Ultimately, our findings shed light on the maintenance, generation, and activation of TRM,
and highlight the effects of viral MHCI inhibition on local CD8+ TRM responses, which should be
seriously considered in regards to vaccine design against viruses that target the MHCI pathway.

Materials and methods
Mice, cell lines, and viruses
C57BL/6 mice were purchased from the National Cancer Institute. Transgenic and knockout
mice were purchased from the Jackson Laboratory, with the exception of B2mfl/fl and IFNγ KI
Thy1.1 mice. IFNγ KI Thy1.1 mice were kindly provided by Dr. Casey Weaver, University of
Alabama School of Medicine. B2mfl/fl mice were generated as described by Bern et al., 2018
(submitted). DC2.4 cells were cultured in RPMI supplemented with 10% FBS (Mediatech), 100
U/ml Penicillin, 100 g/ml streptomycin, 1mM sodium pyruvate, L-glutamine, and non-essential
amino acids (Gibco). Madin–Darby Canine Kidney (MDCK) cells were maintained in MEM
with 5% FBS, MEM-vitamins (Gibco), L-glutamine, 100 U/ml Penicillin, and 100 g/ml
streptomycin. Human embryonic kidney cells (293T) were maintained in Opti-MEM (Life
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Technologies) with 10% FBS, L-glutamine, 100 U/ml Penicillin, and 100 g/ml streptomycin.
DC2.4 cells were gifted from Dr. Kenneth Rock, University of Massachusetts Medical School.
MDCK and 293T cells were a kind gift from Dr. Richard Webby at St. Jude Children’s
Research Hospital.
For the generation of IAV-B819-26 (Flu-B8), the CPXV B819-26 epitope was inserted
into the stalk region of neuraminidase (NA), in-frame, between nucleotides 148 and 170 using
inverse PCR (Phusion-HF, ThermoFisher) and the restriction enzyme AarI (ThermoFisher) to
ligate the mutant plasmid. Co-cultures of 293T and MDCK cells were transfected with eight
bidirectional pHW2000 plasmids containing cDNA for A/Puerto Rico/08/1934 (H1N1) (1  µg
per plasmid) with polyethylenimine (8  µg total). Rescue of the reverse genetic virus was
performed as previously described 155. BAC-derived CPXV viruses were generated as
previously described 36.

Mouse infection and parabiosis surgery
Mice 8-10 weeks of age were sex- and age-matched for each experiment. i.n. and s.s. infections
were performed as previously described 31. In brief, mice were anesthetized and 30 µl of virus
inoculum diluted in PBS was administered i.n. For s.s., fur from the flank of mice was depilated
using Nair™. The following day, mice were anesthetized and the flanks were infected by s.s. at
three adjacent sites, 1 x 105 pfu/site. Parabiosis surgery was performed as previously described
156,157

. Parabiosed mice were rested for two weeks before sacrificing and harvesting tissues.

Immunofluorescence.
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2 x 3 cm2 piece of skin was harvested from infected mice and were prepared as previously
described 158. Sections were blocked using 10% goat serum in PBS for 1h before incubating with
primary antibodies for 1h. Cells were then washed with 0.5% triton in PBS, incubated with
Streptavidin-AF555 (ThermoFisher), washed with 0.5% triton in PBS, and mounted with DAPI
(Vectashield). Stained sections were analysed with laser scanning confocal microscope LSM880
(Zeiss). Primary antibodies were obtained from BD Pharmingen and include CD103-Biotin
(M290), IA/IE-AF647 (M5/114.15.2), and CD8α-AF488 (53-6.7).

In vivo antibody, FTY720, and tamoxifen treatment.
To induce TCR ligation in vivo, 50 µg of anti-CD3e monoclonal antibody (145-2C11;
ThermoFisher) was administered into mice by i.v. injection 16 hours prior to harvesting tissues.
FTY720 (Cayman Chemical) was administered by i.p. injection (10 mg/kg) in aqueous solution.
To deplete CD4+ T cells, 200 µg anti-CD4 (GK1.5) or isotype control (anti-rat IgG2b; Bio X
Cell) were injected i.p. To deplete NK cells, 100 µg anti-NK1.1 (PK136) was injected i.p.
weekly. For intravascular staining, fluorochrome-conjugated anti-CD45.2 (104; BioLegend) was
administered by i.v. injection. Three minutes after injection, mice were sacrificed and tissues
were harvested. Mice were treated topically with 1 mg 4-hydroxytamoxifen (Sigma-Aldrich)
dissolved in ethanol and were fed with tamoxifen diet (Envigo) during the indicated times
shown.

Flow cytometry, intracellular cytokine staining, and antibodies
Single-cell suspensions from the spleens, lymph nodes, lungs, and ~2 x 3 cm2 piece of skin were
prepared at the indicated days post-infection as previously described 31,123. Skin and lung tissues
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were minced and incubated in with Hanks balanced salt solution (HBSS) containing 1 mg/mL
collagenase A (Roche) and 22.4 g/mL Dnase I (Roch) at 37° C for 30 minutes. Samples were
then filtered through a 70 µm mesh strainer prior to staining. Samples for flow cytometric
analyses were stained on ice with Fixable Viability Dye eFlour 506 (eBioscience) before
tetramer and cell surface staining. For tetramer staining, cells were incubated with H-2KbTSYFESV tetramers for 45 minutes at room temperature prior to cell surface staining of the
indicated surface markers. Tetramers were produced in the Immunomonitoring Laboratory
within the Center for Human Immunology and Immunotherapy Programs (Washington
University). Ex vivo restimulation and intracellular cytokine staining for IFN-γ was performed as
previously described

36

. For staining of Nur77, the Foxp3/Transcription Factor Staining Buffer

Set was used according to the manufacturer’s protocol (eBioscience). The following antibodies
were purchased from Abcam, BD Biosciences, eBioscience, BioLegend, or ThermoFisher: CD3
(145-2C11), NK1.1 (PK136), CD19 (eBio1D3), CD64 (X54-5/7.1), CD8α (53-6.7), CD4 (RM45), VACV (Ab19970), CD4 (RM4-4), CD44 (IM7), CD103 (2E7), CD69 (H1.2F3), H-2Kb (AF88.5), CD11c (N418), CD45.1 (A20), CD45.2 (104), CD24 (M1/69), IA/IE (M5/114.15.2),
SIRPα (P84), CD11b (M1/70), Ly6C (HK1.4), Nur77 (12.14).

Statistic analysis
The data were analysed with an unpaired Student t test or one-way ANOVA followed by Tukey
posttest comparison using Prism GraphPad software. Asterisks indicate statistical significance
and p values are denoted as *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001.
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Fig 3.1 Viral MHCI inhibition does not affect the overall development of CD8+ TRM.
C57BL/6 mice were infected by s.s. with WT CPXV or Δ12Δ203 (A to F). (A) The absolute
number of B819-26-tetramer+ cells in the skin (S) and spleen (SP) of infected mice over time. n =
4 mice per time point. Representative of three independent experiments. (B) The absolute
number of B819-26-tetramer+ cells in previously infected skin flank and the contralateral
uninfected skin flank at 49 dpi. (C) Representative flow plots of B819-26-tetramer+ cells in the
skin at the indicated time points. (D) Percentage (top) and absolute number (bottom) of B819-26tetramer+ cells in the skin on 7 dpi and 35 dpi. (E) Representative flow plots of CD103 and
CD69 expression on B819-26-tetramer+ cells are shown for the indicated time points. (F)
Percentage of CD103 (Left) and CD69 (Right) expression on B819-26-tetramer+ cells are shown
for the indicated time points. (G) Schematic of parabiosis experiment. (H) Representative flow
plots of CD103+CD69+ skin CD8+ T cells in parabiosed mice. (I) Percentage and absolute
numbers of CD103+CD69+ skin CD8+ T cells in parabiosed mice. (J) The absolute number of
B819-26-tetramer+ TRM in the skin of parabiosed mice. (K) Percentage of B819-26-tetramer+ cells in
the spleen of parabiosed mice. Representative of three independent experiments (for panel A to
F). Data were pooled from two independent experiments (for panel H to K). Symbols represent
individual mice. Error bars represent means ± SEM.
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Fig 3.2 Viral MHCI inhibition affects immunodominance within the lung CD8+ TRM
population.
C57BL/6 mice were infected i.n. with WT CPXV or Δ12Δ203. Intravascular staining with an
anti-CD45 antibody was performed before euthanizing mice at 12 and 30 dpi. (A) Representative
flow plots of CD45 expression on CD8+ cells in the lungs (Lu). Data are representative of two
independent experiments. (B) Percentage of IV-CD8+ cells in the lungs at 12 (top row) and 30
(bottom) dpi. Data are pooled from two independent experiments. Symbols represent individual
mice. Error bars represent means ± SEM. (C) Percentage of IV-CD8+B819-26-tetramer+ cells in
the lungs at 12 (top row) and 30 (bottom) dpi. (D and E) Percentage of IV-CD8+B819-26-tetramer+
cells in the blood (Bl) and spleen (SP) are shown at 12 and 30 dpi. Data are pooled from two
independent experiments. Symbols represent individual mice. Error bars represent means ±
SEM. (F) Representative flow plots of CD69 or CD103 expression on IV+/IV- B819-26-tetramer+
cells at 12 and 30 dpi. (G) Percentage of CD69 and CD103 expression on IV-/IV- B819-26tetramer+ cells at 12 (top) and 30 (bottom) dpi. Data are pooled from two independent
experiments. Symbols represent individual mice. Error bars represent means ± SEM.
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Fig 3.3 Local cognate antigen enhances CD8+ TRM formation, even in the context of viral
MHCI inhibition and CTL evasion.
(A) C57BL/6 mice were co-infected by s.s. with B819-26 sufficient CPXV (WT or Δ12Δ203) and
B819-26 deficient (B8Y3AF5A or Δ12Δ203B8Y3AF5A). (B) Representative flow plots of B819-26tetramer+ cells in the skin at 7 dpi are shown above the percentage and absolute number of B81926-tetramer

+

cells. (C) Representative flow plots of B819-26-tetramer+ cells in the skin at 35 dpi are

shown above the percentage and absolute number of B819-26-tetramer+ cells. (D) Representative
flow plots CD69 and CD103 expression on CD8+ cells in the skin at 35 dpi are shown above the
percentage and absolute number of CD69+CD103+ CD8+ cells. Data are pooled from two
independent experiments. Symbols represent individual mice. Error bars represent means ±
SEM.
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Fig 3.4 Viral MHCI inhibition evades CTL responses, but does not affect TCR engagement
with cognate antigen/MHC complexes on infected target cells in vivo.
C57BL/6 mice or Thy1.1 KI IFN-γ reporter mice were co-infected with WT CPXV and
Δ12Δ203. The spleens of infected C57BL/6 mice and skin of infected Thy1.1 KI IFN-γ reporter
mice were harvested for ex vivo restimulation and direct ex vivo analyses respectively on 7 dpi.
(A) Percentage of endogenous IFN-γ and Nur77 expression on CD8+ cells stimulated with WT
CPXV or Δ12Δ203-infected DC2.4 cells. Data are pooled from two independent experiments.
(B) Percentage of IFN-γ (Thy1.1) and endogenous Nur77 expression on CD8+ cells from WT
CPXV or Δ12Δ203-infected skin. Data are pooled from three independent experiments. Symbols
represent individual mice. Error bars represent means ± SEM. (C to F) C57BL/6 mice were
infected by s.s. with WT CPXV and sacrificed on 6 dpi. (C) Absolute number of leukocytes
recruited to WT CPXV-infected skin. Cells from the skin were gated on CD45+ and defined as
follows: NK (CD3-CD19-NK1.1+), CD19 (CD3-CD19+; CD4, CD19-CD3+CD4+), CD8 (CD19CD3+CD8+), CD103+ DC (MHCII+CD11c+CD24+SIRPα-CD103+), CD11b+ DC
(MHCII+CD24+CD64-CD11b+), Ly6C+ Mo/Mϕ (MHCII-CD64+CD11b+Ly6C+), Ly6C- Mo/Mϕ
(MHCII-CD64+CD11b+Ly6C-), moDC (MHCII+CD11b+CD64+CD24+), granulocytes (MHCIICD24+CD11b+) (D) Percentage of CPXV+ cells, as determined by staining with α-VACV
antibodies and flow cytometric analysis. (E) Percentage of CPXV+ cells within the CD45+
population. Data are representative of two independent experiments. Symbols represent
individual mice. Error bars represent means ± SEM. (F) Immunofluorescence staining of CD8+,
CD103+, CPXV+ and MHCII+ cells in the skin at 6 dpi. Scale bars, 50 µm.
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Fig 3.5 CD8+ TRM are maintained in the absence of cognate antigen stimulation.
B2mfl/flRS26-Cre-ERTT2 mice and B2mfl/fl litter mate controls were infected by s.s. with WT
CPXV. On 49 dpi, mice were started on a tamoxifen chow diet and treated topically with 4HT
daily for 5 days. Additionally, mice were treated with α-NK1.1 (100 µg/mouse) once weekly
starting on 49 dpi to deplete NK cells. (A to D) Mice were euthanized at 76 dpi and CD8+ T cells
were analyzed in the skin (S) and spleen (SP). (B) Representative flow plots of H-2Kb expression
on CD45+ cells from the skin and spleen on 76 dpi. (C) Percentage of B819-26-tetramer+ and
CD69+CD103+ cells in the skin and spleen at 76 dpi. (D) Percentage of total CD8+ and
CD69+CD103+ cells in the skin at 76 dpi. Data are pooled from two independent experiments.
Symbols represent individual mice. Error bars represent means ± SEM. (E) Nur77GFP reporter
mice and nontransgenic (NTg) littermate controls were infected by s.s. with WT CPXV and
euthanized at 30 dpi. CD8+ T cells were analyzed in the skin and spleen. As a positive control,
B8 peptide was administered intradermally (i.d.) and an α-CD3 antibody was administered
intravenously (i.v.) into Nur77GFP mice previously infected for 30 days. Representative flow
plots of Nur77 (GFP) and CD69 expression on skin and splenic CD8+ T cells is shown. Data are
representative of three independent experiments; total n = 3 positive control mice, total n = 5
Nur77GFP mice, and total n = 6 Ntg mice.
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Fig 3.6 Viral MHCI inhibition evades protective CD8+ TRM responses.
(A) Schematic of heterologous prime/challenge experiment. (B) Viral titers in the lungs of FluB8-immunized mice challenged with CPXV. Data are pooled from two independent
experiments. (C) Schematic of µmT mice skin challenge experiment. (D) Image of infected µmT
flanks (left) and viral titers from skin lesions 4 days after s.s. challenge of α-CD4 treated naïve
control and CPXV-immunized µmT mice. (E) Viral titers from skin lesions 4 days after s.s.
challenge of isotype control treated CPXV-immunized µmT mice. Data are pooled from two or
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three independent experiments. Symbols represent individual mice. Error bars represent means ±
SEM.
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Fig S3.1 Viral MHCI inhibition affects the formation of CD4+ TRM.
C57BL/6 mice were infected by s.s. with WT CPXV or Δ12Δ203. (A) Representative flow plots
of CD103 and CD69 expression on CD4+ and CD8+ cells in the skin at 35 dpi. (B) Percentage of
CD69+CD103+ T cells in the skin at 35 dpi. Representative of three independent experiments.
Symbols represent individual mice. Error bars represent means ± SEM. (C) The absolute
number of CD4+ TRM in the skin of parabiosed mice. Parabiosis was performed as outlined in
Figure 1G. (D to I) Mice infected by s.s. with WT CPXV or Δ12Δ203 were treated with α-CD4
or isotype control antibodies on day -1, 2, and 5 post-infection. (D) Representative flow plots of
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peripheral blood T cells and B819-26-tetramer+ cells at 7 dpi. (E) Percentage of B819-26-tetramer+
cells from peripheral blood at 7 dpi. (F) Percent survival. n = 10 mice per group. Data are pooled
from two independent experiments. (G) Absolute number of CD4+ and CD8+ T cells in the skin
at 30 dpi. (H) Percentage of CD103 expression on T cells at 30 dpi. (I) Percentage (left) and
absolute numbers (right) of B819-26-tetramer+ cells in the skin at 30 dpi. Data are pooled from two
independent experiments. Symbols represent individual mice. Error bars represent means ±
SEM.
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Fig S3.2 CD8+ TRM develop without continuous recruitment of CTLs during acute CPXV
infection.
C57BL/6 mice were co-infected with WT CPXV and Δ12Δ203 and FTY720 was subsequently
administered by intraperitoneal (i.p.) injection on 1, 3, and 5 dpi (A to C). CD8+ T cells were
analyzed in the skin (S), blood (Bl), and inguinal lymph node (iLN) at 6 dpi. (A) Representative
flow plots. n = 9-15 mice per group. Data are representative of two independent experiments. (B)
Percentage of CD8+ cells. Data are pooled from two independent experiments. Error bars
represent means ± SEM. (C) Percentage of B819-26-tetramer+ cells in the iLN at 6 dpi. Data are
pooled from two independent experiments. Error bars represent means ± SEM. (D) Schematic of
co-infection experiment. T cells from peripheral blood (E) and B819-26-tetramer+ cells in the skin
(F) of mice infected as shown in (D) were analyzed at the indicated time points. Data are pooled
from two independent experiments. Symbols represent individual mice. Error bars represent
means ± SEM.
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Fig S3.3 Local cognate antigen recognition upregulates CD69 and Nur77 expression by
CTLs.
C57BL/6 mice were co-infected by s.s. with B819-26 sufficient CPXV (WT or Δ12Δ203) and
B819-26 deficient (B8Y3AF5A or Δ12Δ203B8Y3AF5A) on opposite flanks. (A) Percentage of
B819-26-tetramer+ cells expressing CD69 at 7 dpi. (B) Percentage of B819-26-tetramer+ cells
expressing CD103 at 7 dpi. Data are representative of two independent experiments. Symbols
represent individual mice. (C) Nur77GFP mice were co-infected as outlined in Fig. 3A. Nur77
(GFP) expression by CD8+ T cells from WT CPXV or Δ12Δ203-infected skin was analyzed at 7
dpi. Data are pooled from two independent experiments. Symbols represent individual mice.
Error bars represent means ± SEM.
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Fig S3.4 Flu-B8 respiratory infection generates B819-26 -specific CD8+ TRM in the lungs.
C57BL/6 mice were i.n. infected with recombinant Flu virus expressing the CPXV B819-26
epitope. Intravascular staining with an anti-CD45 antibody was performed before euthanizing
mice at 30 dpi. (A) Percent of B819-26-tetramer+ and NP366-374-tetramer+ IV-cells in the lungs of
Flu-B8-infected mice. Data are pooled from two independent experiments. Symbols represent
individual mice. Error bars represent means ± SEM. (B) Representative flow plots of CD103
expression on tetramer+IV- cells at 30 dpi. (C) Percentage of CD103+TET+IV- cells. Data are
pooled from two independent experiments. Symbols represent individual mice. Error bars
represent means ± SEM.
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Fig S3.5 The number of CD8+ TRM is reduced in B cell-deficient mice.
µmT mice were infected by s.s. or i.n. with Δ12Δ203 and treated with α-CD4 or isotype control
antibodies, as in Figure 2B. (A) Absolute number of B819-26-tetramer+ cells in the skin and spleen
of µmT mice previously infected for 30 days is shown. n = 4-5 mice per group. Data are pooled
from two independent experiments. Error bars represent means ± SEM. (B) Representative flow
plot of CD103 expression on CD8+ T cells in the skin of µmT previously infected for 30 days is
shown next to the percentage of CD103+ cells. n = 5 mice per group. Data are pooled from two
independent experiments. Error bars represent means ± SEM.
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Discussion and Future Directions
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Discussion
Over 200 years ago, Edward Jenner had a theory that prior exposure to CPXV could
provide protection against smallpox. He tested his theory in 1796 by inoculating a child with
CPXV taken from a cowpox pustule and showed that the child was indeed protected against
smallpox. He also made an interesting observation that CPXV infection did not always protect
against secondary infection with CPXV159. It is thus tempting to speculate that my findings on
CPXV-mediated MHCI inhibition may explain this peculiar conundrum. The findings presented
here should also be considered in regards to rationale vaccine design because many viruses
possess the capacity to obstruct MHCI antigen presentation.
Major infectious diseases caused by viruses that target the MHCI pathway include
hepatitis C, symptomatic congenital CMV disease, and acquired immune deficiency syndrome
(AIDS) 160,161. These viruses have propensities to evolve immune-escape mutations and
mechanisms that can render antibody-based vaccines poorly effective162–164. Therefore, strategies
aimed at eliciting strong CD8+ T cell responses and memory CD8+ T cell formation may be
important for effective vaccine-induced immunity against such viruses. However, if these viruses
effectively evade CD8+ T cell responses in vivo by interfering with MHCI antigen presentation,
it will be worthwhile to develop strategies for targeting viral MHCI inhibitors or for augmenting
MHCI antigen presentation. These strategy may be particularly useful in providing cures against
persistent and latent viral infections (e.g. CMV and HIV infection), in which memory CD8+ T
cells can potentially eliminate reactivated latent reservoirs but fail to do so because of viral
MHCI inhibition119,165–167.
The ability of viruses to inhibit MHCI presentation can however be exploited for vaccine
vector development. For instance, viral MHCI inhibition by RhCMV allows the virus to
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superinfect hosts that have established immunological memory to RhCMV72, making CMV
viruses appealing as vaccine vectors168. Using a vaccine vector capable of superinfecting hosts
could circumvent the issue of rapid vaccine vector neutralization by pre-existing memory, which
can diminish immune responses against targeted vaccine antigens. Successful superinfections
could also permit repeated vaccinations against different target antigens while using the same
vaccine vector backbone. Such a feat may be difficult to achieve with vaccine vectors that cannot
reinfect hosts harboring immunological memory against the respective vector, including some
poxvirus-based vaccines. Nevertheless, it would be interesting to explore CPXV as a vaccine
vector since my studies suggest that viral MHCI inhibition may permit CPXV to reinfect CPXVimmunized hosts, although this has not been thoroughly tested.

Future directions
Memory CD8+ T cells, including TRM, may provide cross-protection against distinct viral
strains 169–171. For instance, vaccine-generated lung TRM mediate heterosubtypic protection
against respiratory infection with influenza virus 127. TRM have also been shown to provide
protection in the skin and genital tract using a number of different viral infection models123,124,128,
demonstrating that TRM can be excellent antiviral vaccine targets. An improved understanding of
the processes that govern TRM development and activation may thus aid in the design of
efficacious TRM-based vaccines. Others and myself have shown an important role for local
cognate antigen in TRM development and activation133,134,136,172, yet the mode of local cognate
antigen presentation (i.e. direct- or cross-presentation) used to prime or activate TRM remain to be
elucidated. Determining the relative contribution of direct/cross-presentation and how these
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modes of antigen presentation affects these processes is challenging, but can likely be addressed
using the CPXV murine infection model.
There are several advantages in using the CPXV infection model. One is that the priming
of naïve CPXV-specific CD8+ T cell precursors during CPXV infection is dependent on BATF3+
DCs, the main cross-presenting DC subsets. Local BATF3+ DCs also remain uninfected at the
site of infection, suggesting that BATF3+ DCs are actually cross-presenting antigen. Another
important factor is that the contribution of direct presentation by CPXV-infected cells at the site
of infection is likely minimized due to the effects of CPXV012 and CPXV203. These points
strongly imply that cross-presenting BATF3+ DCs provide local antigenic stimulation to CTLs,
thereby promoting TRM formation, but experiments to directly test this hypothesis need to be
performed. Interestingly, the findings and points discussed here also raise the possibility that
local cross-presentation may be involved in TRM activation. However, additional experiments are
also required to determine the role of local cross-presentation during secondary CPXV infection.
The CPXV infection model therefore provides an exceptional opportunity to investigate the
mechanisms of local antigen-driven CD8+ TRM differentiation and activation; further studies with
CPXV may ultimately facilitate the development of improved tissue-specific vaccine design.
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